Home

新しい結核用語事典

Contents

1. annual report on reg 1996 Te
2. W INH RFP X ST DEEZ PARVEZ TB
3. onset of tuberculosis X
4. D R cross resistance A B A B B A
5. 1987 PUNTA GVA SERGE tuberculosis infection 46 ERE DORA Beh
6. Infectious Diseases Con trol Law 1998 2007 DARK Infectious Diseases Control Law
7. SALTY pK miliary tuberculosis of early generalization type J eS RAT OSE NE E gt SLAY ocai emphysema WUE ISOS AVENUE PL
8. adequate treatment gt Pe REALE Dubos medium Dubos 1946 80
9. LA Wi DKW second line drugs EB PZA TH CS Tbi VM KM CPM EVM PAS First line drugs a b Sec ond line drugs
10. peripheral nerve disorder INH 10mg kg Bs 107 EB TE EMI PIO A AE DE chemoprophylactic case cmronic bronchitis COPD I DD ROR BL 3
11. 8 DOTS Directly Observed Treatments Shortcourse DOTS BCG
12. gt 719 54 bone marrow biopsy BAERI bone marrow puncture Robert Koch 1843 1910 1882 3 24 WAZA E T y RA EIR
13. HRA CS IRE H A 51 DHR DAAA antipiotics restrictive ventilatory impair ment SRE J AIE hypercapnemia CO BSE ER L RETR BRE lt AUTH
14. bactericidal action effect MAPS VC HUA DN PBS Rie amp surveillance
15. DOTS prothionamide DUFFI F PT physical therapy physical therapist PZA PZA pyrazinamide mEIVYIF IF R Ranke DF Yy DRED Rasmussen s aneurysm DFA A y e YERE respirator AANA i a a RFLP restriction fragment length polymorphism RELP DNA finger printmg I56770 LOMA IE CH YN
16. 1961 445 9 rifampicin RFP 1957 Strepto myces mediterranei 1966 1971 8 IR
17. BY 55 F T
18. Hi generalization of tuberculosis PALM ae BAMA E L 95 sco selective health examination vestibular disturbance 3 2
19. cancellation from registry registration rate prevalence rate of the registered 10 10 1 1961 1961 1713 doctor s delay
20. OWE REOR ONE OR OREM curettage under thora coscopy 44 d bridemant a thoracoscopie HOES MRE OH E EERE dy ZV Lee thoracoscopic surgery 3 4 ROACH FERMEI thoracoscopic curettage Nie hi FE OD IF SE IC Yo A FRM RDS TS FA thorac
21. EB desensitization Hi RFP INH PAS DE DIT LVF health examination detection by health examination erythrocyte sedimenta
22. S Siti 62 X tuberculosis epidemic outbreak of tuberculosis
23. gt KEG p ZZ il intractable tuberculosis X BLO MAAN CZ Al RFP tuberculin non reactor after repeated BCG vaccinations BCG CO narcosis PHAR AP VA YA secondary infection type atypical mycobacteriosis
24. HD case management L REP SAT CNOMEALO bik
25. PERT SOME BR open healing exogeneous reinfection RFLP HIV E p Ogawas medium proportion outpatient ambulatory treatment method pT REAR
26. He 4B RIC SOA OPER L eon ee fs case registration card EZ case notification 12
27. physical therapist PT 3 B incidence of disease 10 10 1 BK MAREEK
28. 1962 1990 ATS 2003 2003 2008 2007 ATS 10 2 1 JRE AB IRS DIERE
29. bacterial pneumonia TFIA KIRA MRSA Branhamella catarrhalis t cycloserine CS 1955 3 Streptomyces orchidaceus S garyphalus S lavendulae dulae DRRR b TLS ABN ACTH S nepi 1959 8 1
30. case finding 80 16 4 patients card indicating method of approved treatment sensitivity susceptibility test gt A RTE AR
31. HERE PCR surgical treatment Wie RY KT SO WI 28 30 RFP
32. response rate to health examination LEDES TED BD EER passive case finding mp EE bb Schwartzman reaction G Schwartzman 18 24
33. 75C 500 1 000 gt Ture Hie tuberculin reaction Y tuberculin BCG Koch HRA TY
34. target point symptomatic visit to doctors Wi HREOAMHERE HA 80 T prevalance of symptomatics drug allergy BOF Y YSN Bii
35. 129 3 6 Ro 70 II 1 1
36. R intermittent positive pressure breathing IPPB intermittent treatment 2 3 p sensitization interstitial pneumonia
37. 4 2 OFT AARC IC BR QFT OFT 4 3 TNFa 50
38. compliance adherence cooperation gt RAE p wie 56 JE
39. Schub Schwartzman reaction SM streptomycin spirometry Stop TB Partnership WHO 2 2000 2007 500 WHO DOTS
40. 2 M kansasiiiE M szul RARE LUT WW BCG
41. NGF REEMA Ze SS D first line antituberculosis drugs major drugs RFP SM INH PAS 3 RFP Firstline drugs a b Second line drugs 1 one second forced expiratory volume rate FEV 1 forced exspiratory volume in one second FEVi aetection by medical institutions
42. 2 HES GET R7 11 8 4 9 27 5 2
43. 1993 cough JRA ARRIR 5 Ba cerebrospinal fluid CSF examina tion PRM AR OBA LAE AR MAERA E ADER
44. ELISA ELISA E AA VBR SC tuberculosis of bladder PETTY D gt D RAY A DSR AG a UC tS LIE EMO RRA DEEA RET UC AE C Fei DSH ARTE L CHR PERIK WR E ZE HORER O ORME UEL A gt DIRE g public health nurse 1941 2
45. OL 24 registration system HH VE
46. AAW Cis LWE 1 200 so 200 500 9 H 500 2 000 HH 2 000 pulmonary lung physical therapy PPT LPT DIF gt high risk group BCG BCG
47. plain chest radiography X Tse PM Mi Ae BES Aes cold abscess in chest wall Was ed BARAK IC k o CHER SAS pares 35 REO Al Iho fib oZ
48. gt 7T RIVE DO nosocomial infection 15 1998 5
49. DML A A AT acquired immuno deficiency syndrome AIDS Zz laryngeal tuberculosis RIKE ADU EBL Cd SICH FLFHOESHSD WEP HAM WIC MNT BA DNA examination of laryngeal swab 3cm 90 far advanced cavitary type 1 X
50. prothionamide 1321TH 1969 11 N CHzCHzCHs Zo CSNHz molecular epidemiology IS6110 RELP restriction fla
51. MEEA bronchial brushing X AME HUES SAIC ED REVERE LHS bronchoplasty 29 bronchial biopsy 7 gt TA N AI TRRICBUT
52. booster phenomenon BCG BCG 2 1 HS
53. 1 1 breathing exercise BE degree of dyspnea pea Ya Y AUP PA MERE respiratory acidosis respiratory alkalosis RAS respiratory ventilatory failure insuffi ciency O2 60Torr Oz 1 CO 45Torr THC 53
54. PPD PPD tuberculin reaction BCG 8l YNZ Y Y ZEEF S 48 T
55. Be radiography X airect vaccination BCG 1960 BCG
56. AL bronchoalveolar lavage BAL bron chofiberscopy AE BOTT 7 fiberoptic bron choscope DAE LIRE TEJE bronchial fistula AE EDA ORC BL
57. kaolin agglutination test AAY VAP ICH L L CHARA DY VRE DRI F ELISA TE chemoprophylaxis INH T
58. n SSMS ALLS SEE a PAYA y ABA semiliquid agar medium 0 1 HEE photochromogen photochromogenic mycobacteria D 1 24 M kansasii M marinum 2 Msimiae M szul
59. ZR IF 70 air plombage GEIRE MSW 16 We BOARS Tr acquired immunodeficiency syndrome AIDS HIV T
60. 1 31 2 60 7 6 DEIR case notification atackrate para amino sali cylic acid PAS 1920 1943 Lehman 1946 1950 Wh 1951 4 10 1 10 15s UL COOH ae generalization
61. Hinterleukin IL IL l IL 2 IL 1 NK B IL 2 THI NK B negative conversion reversion BUG
62. INH 2 8 RFP 1 0 SM 7 0 EB0 9 MPR0 7 2002 Middle brook Dubos hemoagglutination test LS BRIT ST SHURE MET ATEO ELISA 108 D gt ELISAK BETTY MID DAA VEE FJ b Y Middlebrook media 7H9 7H10 7HI1 7H9 MGIT Septi Chek BacT Alert Hehe LCN
63. 3 health examination in the enterprise X optic nerve disturbance EB
64. MALL CAM WH HSH MIO FEB gt Hi bacillary dose WADE He DNA VK IC AAO LA ICRBEA THD virulence J lt segmental shadow
65. antitubercular agent Bs 2004 2004 INH REP SM EB KM TH EVM PZA PAS 50 D 6 9 2 3
66. 1 SM SM ORME 9 DHSM SM adverse reaction gt TUR AER PURI BE pia double barred cross Godefroy de Bouillon Duke of Lorraine OFA PROBL 19024
67. treatment standard 20 2 HUGE SN 2007 3 121 public subsidy for med ical treatment 37 1 2
68. CHA MA Ch 4S gt Ho BE pleural adhesion and thicken ing X X
69. HY tuberculous coxitis positive end expiratory pressure ventilation PEEP 5 20cmFlO FRC 2 PaO ARDS PEEP respiratory system dysfunc tion WBA
70. cavernostomy Fr OW WL cavity healing ORR PEATE WHE
71. V WEE OR IEZ EORR AN middlebrook 5 83 lyophilized freeze dried vaccine BCG gt BCGI7FY liaentification test
72. WHO 2 90 WHO BCG BCG positive tuberculin conversion after BCG vaccination BCG DNCB 1 3 6 BCG BCG ii Leea BCG
73. INH 18 9 RFP 11 0 SM 14 4 EB 8 4 9 8 2002 TB 32 MPB64 Mycobacterium protein fraction from BCG of Rm 0 64 in electrophoresis MPB64 BCG Tokyo MURER 98 99 MPB64 M tuberculo sis WIPRO FETE LTS resting bacteria bacilli
74. mass health examination for general inhabitants 65 colony L 1mm 4 R S R 8 R 5S WIC SMASR volume controlled ventilation gt A TIM D BP ere i az motivation for regular treatment visit ing medical institutions
75. BCG vaccine gt BCG booster phenomenon gt T AY WK Boyden s hemoagglutination test DRI F Y ke C caries y A ciprofloxacin eyFua7ustyy CO CO narcosis cohort analysis colony compliance COPD chronic obstructive pulmonary disease cord factor 1 FF7773 cord formation CPFX ciprofloxacin CPM capreomycin CR computed radiography D meayea Fy FSFI CS cycloserine 70r y CT computed tomography Iy Ea eh cyanosis aT TI X D danger group aTAYY TNV T DDH oon Mycobacteria gt IERIE DHSM dihydrostreptomycin dihydrostreptomycin DNA DNA probe DNA
76. 49 a high voltage radiography X X AVY JA OK X 120 150kvp
77. 5mm 10mm BCG Lk potency of tuberculin E TU 1953 WHO PPD S 0 02ug 1TU 2TU 5TU PPD 0 05ug PPD S 2 5TU extraordinary health examination
78. AT BOTEI ME JE secondary infection K secondary tuberculosis 86
79. initial standard treatment 2004 A PZA B A RFP INH PZA SM EB 4 2 RFP INH EB 4 B RFP INH SM EB 6 RFP INH EB Sen et primary infection CORD MAIC gt RE primary infection tuberculosis PTY OFS primary lesion focus
80. ELT DFM Lo CHOY S DENET SII aE thoracic empyema due to bronchial fistula AAE SED AO Mk it UC DH REK X gt TELE closure of bronchial fistula H
81. 8 AES TUBERCULOSIS AND AIR TRAVEL GUIDELINES FOR PREVENTION AND CONTROL WHO 1998 WHO TB 98 256 130 1 2 1 3 2 3 8 3 1 2
82. tuberculosis prevalence survey 1953 1973 5 5 1953 51 011 99 1973 45 682 86 X 1973
83. TORBIE ETC K 44 A
84. cyanosis cynos F WHS H QO 100m 5g CO O 70 regional difference in
85. BELO A MED 5 AEN 3 WOR CIM 1 EILO TE EEE OF OF Le E CHAIRS MEETS iR yy empyema related lym phoma iT EWR AO A TURRE B
86. bronchus pl chi 20 40 40 60 BL 16 18 0 5 1 0mm U WIRES KY KIT bronchiectasis
87. 1 2cm elevation of the hilum V X pulmonary markings X Mi Wy hilar lymph node ERM CHS
88. 6 12 24 secondary pneumothorax gt ER Dateral view radiography HAA ESLER DMA CM TT A gt D XR EI S AE
89. pulmonary encephalopathy DUT AFVA YA HHR lung resection WE WIAD MALAY 2 ABEL pulmonary fibrosis
90. tracheobronchoplasty SUP 9 2 EIR L TRAIRI LYST ZERRE BH SD AY 7 tracheobronchial tuberculo sis KELOR RRS FILT SC EBH PE ME X
91. RFP DEORE intracerebral tuberculoma CT MRI cystic shadow HO CRED BV ETUC WABI HERE PEPE eT OTF TUT KELET OM E ok pulmonary aspergillosis Aspergillus fumi gatus WER ABPA WA REN HEA O ll CHz CH2 CH2 CH
92. stable non cavitary type X W AMI l TV DEK fe EE mycobacteria PNY A gt DH D Ds oa fH Zee LE RTT E M scrofulaceum M gordonae M szulgai M szulgai 37C 27C EEA scotochromogen scotochromogenic 13 1314TH ethionamide IFFHS F 1321TH prothionamide
93. DOTS OZC cohort analysis BE CL Att OUR amp ER LT amp colony inseparate admission of tuberculosis Patients to a general ward Frost 19 20
94. 1 QFT PPD BCG BC BCG PPD BCG BCG PPD
95. 1945 Chase 1907 Pirquet BCG BCG OWE E PPD 0 05ug 2 5TU 10mm Bem eriterion of tuberuclin test reading PPD 48
96. cirrhotic reaction HADI STRESS AHL AKE cavity with sclerotic wall RFP CS
97. T 17 routine health examination 53 2 X 65 Z KE QI
98. SV LEAL L HID b OHH BEHEIC k o CHINO take eZ high dose therapy INH1 0 5 1 0g multinucleate d giant cell HEAP BR ISVS THD DRA ae Takahashi s kaolin agglutination test DHT YRS polyclon
99. 2 12 15 BCG surveillance of BCG vaccination BCG BCG MAS BCG side adverse effect of BCG vaccination BCG HER Y BCG S BCG
100. gt LE A KE productive reaction L relative risk RR D A fe REA CBRE S NENDRA URMESNEPORRNOY AZ drainage bronchus shadow HAY D 22M CIE Ze D AE SCC LAY LE OZE SUF SCRE LAME AP HAGE WER
101. 2 SM KM EVM CPM CS RFP INH EB TH PZA PAS RFP INH SM PZA REP DF ERA Nucleic acid amplification method DNA RNA DNA polymerase chain reaction PCR RNA transcription mediated amplification MTD
102. NTA 1974 EAT SEN Dia NTA DUSTED DAK tuberculosis like MAC SiC UL 5B RE PEI BSE D HEAR amp FE IC EREMO ENES RA EA A PRAJE CMEC SN ATEMDASH M Kansasii MAC HOT TUB LUNG pulmonary hypertension 30mmHzg 20mmHg 12mmHsg
103. lung cancer bronchogenic carcinoma ALANS CP EB PLB BENIN WFE WA CRATE WROD pulmonary function test collapse therapy of the lung 9I
104. BCG D tuberculosis advisory committee 24 3 statistics of tuberculosis 1974
105. endoscopy endoscopic examination ee Oe ee RAE SC BL TR RES E CLR AT HEC gt RE endoscopic surgery endocrine disorder TH softening and liquefaction HEARED
106. pulmonary sarcoidosis IN y ACE 92 AVIV gt BALF CD4 CD8 Ga PROB
107. BCG 9 726 16 6 PO 1
108. 2 3 6 bovine tubercle bacillus Mycobacterium bovis my Y AA J bovine tubercle bacillus Mycobac terium bovis gt M bovis Ai DRE right ventricular failure right sided heart failure RHF H MERER JEK congestive heart failure
109. AH AR HTK AB RIESS EaD ae B ita amp E congenital tuberculosis WAT MICA Y
110. ee aecortication PE AT CPR SS CE BBV 1950 posteroanterior view radiography P A X
111. DAELE cold abscess SINE RENE epithelioid cell respirator Ri LAMY 77 7 OSHS CH aNYFL F7 L wenstein Jensen s medium L J m F VHA L WME ERE BOL MDP CD4 T DIZ AERE DRE
112. drug sensitivity drug susceptibility test 2000 1 1 2 1 S 1 R 770 2 3
113. gt iti ry a guidelines for mycobacterial examination V 1949 1950 1964 1979 2000 2000 LPL 2000
114. 1 1 1 x100 PaO 1 20 PaO 50Torr 3 20 30 PaO 50Torr 60Torr 4 30 40 PaO 60Torr 70Torr respiratory function test O
115. 3 6 1 8 1 2 3 zeno 723 ff sa eme ewe Wee PEME suun mune SM BR spe ALOT gee onne ma mo AAEE aA mE i i KM Hag EVM REL OT mime au INH h
116. classification of pulmonary tuberculosis on X ray findings Laennec V 1907 Turban Gerhardt 1922 NTA X NTA 19434F NICE YO XW LO D 1957 1959
117. 10 1 Ma 15 DOT desensitization gt WEE defaulting drop out 2 3 Sh multlocular cavity
118. reactivation REP ATER DAM CHS LENA gt THE bacteriological relapse TRICK Oo KARTEL EME OR F MR OD Rt FRE bacteriological relapse rate
119. X bronchial perforation yiI bronchial washing lavage 20m L
120. welt caseous pneumonia WARIS k AREE ZE o MOB E HAN REEE D WAL ve X caseous pneumonia type lesion EL X VERE e ETS
121. pre allergic phase TL TAO BRR SEU Ts bY RV YY SSS 2 10 4 6 grade of bed rest and exercise status R 1 8 5 1947 1950
122. protein of tubercle bacilli PRO WK HEM L D SV LRRD 5 PPD MURA A PD mycobacteriophage PRIS DS HD TORRE tubercle
123. 21 classification of pulmonary tuberculosis designated by the Japanese Society for Tuberculosis GAKKAI classi fication PROBE WA WU Cr b X 1 V 1 3 ASK hemoptysis AI E Zaid gt Ze MH EMT SOE We amp BUC S Ne MLNS EAL CHIR ME PSL aassi fication of pulmonary tuberculosis designated by the Japan Research Comm
124. upper lung field X ST PRO S L 2 WMR lobular shadow 1 2cm X initial chemotherapy initial primary drug resistance initial treatment
125. Oz tuberculosis of male genital organ EARN ORAA IL ZEL J tomography X CT single drug therapy monotherapy
126. miadie obe syndrome MANNY HR CERES MRE LIEKE L H PREU amp AP SCI ISIE LO HE RIET PREKE E middle lobe and lingula Mycobacterium avium intracellulare complex MAC MAC MAC Uy mesenteric lymph node tuberculosis BA DV LAL EIS HRT TK 72 1 long term chemotherapy RFP SM INH PAS
127. segmental resection HEEL 1 2 38 airbome infection TALL DAT RAVEL 5um droplet nuclei 50m N95 cavity
128. VER CV 10 10 1 positive tuberuculin conversion by tuber culosis infection HLT BCG persisting bacteria bacilli persister RFP tuberculosis of the knee joint medical facility designated for treating tuberculosis 6
129. 2 1 2 3 8
130. tuberculosis mortality death rate 1 10 1940 EL WHO 9 A B15 1899 1918 257 2000 2 1918 15 19 619 18 19 2
131. subculture PRA 40 gt oy BERG AE portable oxygen H QOL Oz EFS Oz 200 400 500 1 0007 O WT FE
132. 1 18mg kg 1 0g 2 12 5mg kg EB index spontaneous pneumothorax LT X gt es TES natural resistance
133. M avium complex WINOK Ch SPORE TIT I DNA HS TB DNA DDH other cavitary type IL
134. activity classification CHS HRA ARETE X home visit 53 14
135. impaired pulmonary function tuberculosis low prevalence country Styblo 0 5 0 5 1966 10 30 0 4 10 2 5 8 DRAEK SEEK SRK danger group
136. 1 2 1 127 1 K1 1 1 2 3 2 1 2 3
137. TB G 118 120 121 1 124 126 W227 133 a 0 1 Bac I Il IV VEGA fa 3 H PL Op b 1 2 1 3 3 c r
138. dormant gt HR IL Tai avian bacillus Mycobacterium avium by avian bacillus Mycobacterium avium M avium forced expiratory curve forced vital capacity FVC niacin test Hi HLT 1956 85 95 endogeneous reactivation
139. DRAAI K V KERRE natural resistance congenital immu nity WAS 72 IRERE k 1 early generalization TOA AHR CHARA DEAT S W
140. 2007 ASK prevention of infection ERR DT N95 SFHR SRAKAR contagious Parameter
141. IEE blood gas analysis BGA pH PaCO2 PaO2 SaO2 ERRE HCOs 20 pH 7 35 7 45 PaCO 35 45 Torr PaO 92 Torr SaO 97 HCOs 22 26 mmol 7 PaO PaCO PaO2 pH HCOs SaOz SPO DAM ECA
142. APTN V eighth cranial nerve distur bance PAYER HIRE SIRs HAC aa HE TEOD EAM EO ACAI SM KM CPM VM EVM 1 SM KM CPM VM EVM Ase iS tht plombage of omental flap MEMEO FAS AT RWE PSH
143. Mleprae M visibilis Runyon Se BRS 2007 121 AN SHOE tz 1 5 a seep gaa By TES aken gop 1 BEEE apg 4 15 ae xZ 1 5 30 3 lt 1 15 1 1
144. C D 1 3 120 M tuberculosis M microti M bovis M caprae li M africanum M canettii M pinnipedii M kansasii M simiae I M marinum M asiaticum M kansasii M gordonae M botniense M marinum M heckeshornense M cookii M intermedium M doricum M lentiflavum M farcinogenes M szulgai M hiberniae I M bohemicum M kubicae M interjectum M tusciae M nebraskense M palustre M parascroful
145. VC VC VC 80 1 1 FEV FVC 1 FEV1 1 FEVi 1 FEV FVC x100 FEVi 70 2 VC 80 FEVi 70 w VC 80 2D FEV lt 70 VC lt 80 2 FEV 70 VC lt 80 FEV1 lt 70
146. WK 2 FBO BATH d SDS RERE GBD SB RIEDIDIEL lt FER iB 7 PERU amp Mm AS dO IRE ME MEI bronchoscopy bronchoscopic examination CCD HS
147. RFP TH INH EB 3 1 M scrofulaceum FE infections caused by M scro fulaceum KPE CHE FEAT M scro flaceum CED ADE OHEBBULA Ze vs M gordonae KM RFP EB M szulgai infections caused by M szulgai 37C 27 C M szulgai REP EB TH SM N NAP p nitro a acetylamino B hydroxypropiophe none NAP
148. IV V D EAD DEH latent tuberculosis infection Sh 71 special care law for injured veterans 1963 BCG generalized BCG itis BCG BCG BCG
149. Sbyblo 11 13 canalicular spread dissemination BES DOREEN LT Ii D A OSG ATS A DSA DS caseous necrosis 0 ORRIA RIE OLMIS KZ FEE FATED L amp O CI CARE WORE ORA A
150. IELIEK LCA MMO JA amp 2 Langhans giant cell RF OFA DAN ARAB EAR UC Rankes classification Ranke 1916 IL Arn PANEL ICAL Le Ranke I Ran
151. 2000 G8 1990 Alt 1999 T 2007
152. 5 4 1 EL OFT 10mm 5mm 737 20mm 10mm QFT OFT 10mm 5mm
153. X treatment required ETM PEK Bas follow up required Ea PEK sick leave off work required light work required normal life under follow up RET PEK onset of tuberculosis from recent con verters 1 2 BCG BCG 777 predicted vital capacity pred VC vaccination BCG DHE IIT SPUR
154. Wm tuberculous granulation L tuberculous thoracic empyema gt jR ERROMARA disease stage of tuberculous thoracic empyema 1 38 1 3 3 tubercuious pneumonia
155. ADVI PF P gt IE AME 97 miliary tuberculosis of late generalization type KAROD b PEI E K V RRS NDT ED EW E A MEM RATA I TS SE gt ALTE RIESA scar formation cicatricial healing proliferative reaction AS ERE
156. acid fast bacilli HIRE bO HODRA OME NATHRACH 3 HRA DAA DIERE SIERE acid fastness ELA ETERS
157. 6 962 management of regular drug taking DOTS dosage RFP INH INH REFP EB 1 1 PAS TH 1 3 drug taking rate
158. PPD 2000 PPD DRI NUZ YY thoracoplasty EARMS SPB OD WAY EU ETO hi 5 2 deformity of
159. DOT DOT Observer direct smear examination WEE SO WO ACAD EL ELBE ASHE CRYO DF RVE PT TA gt smear positive and culture negative bacilli SPCN ARF CIEE OD BRAS CUBR A DS A EA DICH EM Chok TA ROES E AV CRURT OY RFP 2 3
160. costophrenic angle X 115 CT A costal caries tuberculosis of rib rp costal tuberculosis HY
161. HIV inactive pyrazinamide PZA inactive tubeculosis 1952 1957 4 1996 4 INH RFP PZA SM EB 4 2 INH REFP 2 INH RFP EB 3 4 6 1 15g KJ proportion method gt HA RSC HEAR von Pirquet C 1874 1929 L
162. W El 2 2 4 7 Anti tuberculosis Women s Society 1950 1963 1975
163. Stop TB Partnership Japan Stop TB Partnership 2007 NPO streptomycin SM 1944 Waksman 5 Streptomyces griseus 1951 10 1 1g 2 0 75s SM SM SM NH OH NH BO HCN
164. M kansasii 98 PURRE Ka ER ARICA L M avium M intracellulare M kansasii DAK EMT SHIP ICAL SUR diagnostic criteria of atypical nontuberculous myco baceriosis
165. 3 EBA slow grower HRKI EFM WEH RRE RKA CWA Ze M fortuitum Af c7e ozze WRASSE ICAMS NCAR 1 HAY IDS VJ delayed type allergy delayed type hypersensitivity DTH 78 24 72 DTH
166. OFT NM 134 IEN y IFNE IFNN IFNC IFNN IFNM IFNN 3 IFN y ESAT 6 CFP 10 0 35IU mL 0 10IU mL
167. 95 Wy hilar glandular tuberculo sis FIBRO ORWELL COMERS HE X Wi lung field X culture cultivation HET 37C al DT SL
168. X 6 partial resection 94 Wh OSHA 5 BEAK IC YY alveolus pl oli 250m 3 143m2 TH HZA W be CHD IT 1 90 thick por
169. Ke 5 HIV TNFo 3 QFT 3 1 Gold standard Mori SILA 1 119 13 86 54 66 QFT 89 0 95 81 9 94 0 CDC OFT 23 91 95 73 98 79
170. false positive 2005 thoracoplasty onset of tuberculosis from remotely infected pleura
171. 2 SORA BCG AHA SS BCG 1967 sensitive bacilli O k 4 eR ASAT REER E b TA RERED LS AMR SLE RR CHAE RHR cold abscess MAERED E BERO L SICA ARRI k DIRE LR Ze 0 FAK WRT ILE Ct PE GGL DEIRA sensitive drug gt SE PERE Al radiophotography RP RGR a Le Xm BOG
172. RALF Snek gt EA TE IE ZS erythrocyte sedimentation rate ESR spinal caries tuberculous spondyli tis 70 80 WORI calcification HEAL HEADS
173. 3 E9 4 N95 5 6 3 7 HEPA 0 3 99 97
174. World TB Day WHO 1997 3 24 World TB Day 1882 3 24 WHO 3 World Health Organization WHO 1948 191 2000 1951 6 WA
175. public health center 518 2007 A corrective thoracoplasty
176. 10 10 1 1973 SEHR thoracic empyema with bronchopleur al fistula AEE AREER IREK
177. 60 37 management standard X Wi A B C D 4 1 2 3 3 1 2 3
178. miliary tuberculosis Re SAVE TENY X 1 2mm X FEIR AERE EDR REP S EAR 74 postural drainage PD PEO WE Hy EIS L
179. 6 6 cohort meeting DOTS DOTS DOTS DOTS T
180. pneumothorax therapy SM REP gt Wi regular drug taking OM H OF BRIE L gt SESS acquired drug resistance
181. BARI LC TERA coagulation necrosis gt CRE pleural effusion SVL HEB te CM A OMB KY BG BRO FIE ADA DS
182. TEIR bronchial stenosis e ELUI BD bronchiectasis broncholith TASES VX MILE lt P WA IL A
183. Waaler Dye liquefied oxygen 17 9007 50 70kg BCG axir lary lymph node swelling BCG FRA 1 SERCA 5S WRG 7S DIER BCGHEMIE
184. Gaffky Robert Koch Hh 1 10 Gaffky scale 1 3 1 G2 2 G5 3 G9 KAR 7
185. 5C 2 UAE 7 FY ethambutol EB 1961 1967 1 075 1 0g 1 2 PUP EC DES C2Hs CH NHCHCH OH CHzNHCHCHOH Cos 2HCI ethionamide 1314TH 1956 Lieber mann 1963 5 Att 314TH EB EBET 1 0 3g 0 5 0 7g 1 2 3
186. Koch s phenomenon BCG 1 2 cord formation cord factor 1 1 TORBAT SNS HER
187. NHRD THEW mp FEAL IS A acute respiratory distress syndrome ARDS ARDS EH acute empyema pyothorax gt EI molecular sieve oxygen con centrator O Oz 90 0O 57 HRMS Hide b BUH S tv old tuberculin OT 1891 Koch
188. 1 67 3 6 ELON idiopathic pleurisy WEE FOIR S NRR X 84 virulence HO 1 1L000mg
189. EL WHO RT23 further examination 27 2 X V 53 13 Global Fund to Fight AIDS TB amp Malaria 2000 G8 WT
190. perifocal inflammation HABE CUE Ze Vs X concentrated acid fast smear NALC N acetyl L cysteine NaOH Sodium Hydroxide 2000 Wy g
191. thymus ko TEMRE TL NEO PIAL B OHA AMM CHET T pleurisy gt EEE MALE extrapleural plom bagel PALER highly virulent bacilli E PER LEED Oa a
192. 5m 12 17 27C 2005 4 IF X transbronchial lung biopsy WAZE TBLB 39 AAT X fluorescence microscopy HUB BRR AO K 1938 Hageman AAW E BOCES CHE
193. BACTEC MGIT 960 BACTEC 9000 BAL bronchoalveolar lavage DAE SCNT ADE BCG Bacille de Calmette Gu rin Calmette Gu rin ko TEONA Y VMDC WS 1909 We 5 3 13 230 1921 1924 1925 1965 172 Tokyo 172
194. BREH BREET SY AZ ASHE GRRE O LTO 10 2 1 RREME x A 10 0 1 9 9 0 risk of infection source of infection O 26 isolation of source of infection
195. mechanical ventilation 1 1 2 volume controlled venti lation pressure controlled ventilation 1 DERA TIPR SEERA TIPK ventilator respirator AANA i a a exudate M Light 1
196. 2002 3 2007 6 000 15 world ADS Day WHO 1988 12 1 World AIDS Day AICS ZG ee OO Fete HEM Ue 1996 UNAIDS 69 UNAIDS
197. in vitro Wy lymphatic spread dissemina tion lympho hemic hematoge lymph node perforation scrofula scrofulosis
198. 5 A I SEE ZR T WA Vol 79No 8 503 506 2004 732 TB G 18 5 BCG TB 2G Cellestis OFT K 2005 4 2006 1 BCG
199. AR ak R F Vol 81 No 5 393 397 2006 739 142 144 ADA AIDS ALA AM ARDS ARI ARTI BAE BAG BAL BCG BE BG BGA CMI COPD CPFX CPM CR CS CT DHSM DNCB DOTS DTH EB ELISA ESR EVM FDA FEV FEV1 ma adenosine deaminase acquired immunodeficiency syn drome American Lung Association atypical mycobacteriosis acute respiratory distress syndrome annual risk of infection annual risk of infection bronchial artery embolizaion bronchial arteriography bronchoalveolar lavage Bacille de Calmette Gu rin breathing exercise bronchography blood gas analysis cell mediated immunity chronic obstructive pulmonary dis ease ciprofloxacin capreomycin computed radiography cycloserine computed tomography dihydrostreptomycin Dinitrochlorobenzene Directly Observed Treatment Short course delayed type hypersensitivity ethambutol enzyme linked immunosorbent assay erythrocyte sedimentation rate enviomycin Fluorescein diacetate forced exspiratory volume in one second one second forced expiratory vol ume rate 142 FVC HIV HOT IGRA IL INH
200. DNA 20 RNA DNA DNA RNA DNA RNA PCR RT PCR MTD Amplicor WEMEL L AccuProbe PCR DNCB DNCB reaction DNCB Dini doctors delay trochlorobenzene 2 3 DNCB 48 DNCB doctor s delay K y FAV
201. isonicotinic acid hydrazide INH 100 intracutaneous intradermal inoculation 0 BCG 1928 Wallgren 0 05mg WKS CHE PIR amp HES S F WHO 1967 non photochromogen nonphotochro mogenic mycobacteria MEEK k HELA T O Chills CS Mavium M intracellulare M nonchro mogenicum complex M xenopi ts
202. RS SES DAE Save bronchography BG X L BEA ORM E tee LCA SC 30 ORE CT bronchial arteriography BAG AL BAE BAD bronchial artery embolizaion BAE
203. oo Boe uty e lo 30 0 300 8 Go 1 2 30 1 2 300 G1 1 2 20 10 19 100 G2 2 22091088 10 100 G5 3 100 1 z10 1 G9 500 R H E 0 o E 1 1 4 2 1 3 1 1 4 1 2 3 5 1 4 6 6 1 7 12 7 1 13 25 8 1 26 50 9 H 51 100 10 1 101 capreomycin CPM 19604F Streptomyces capreolus 1967 1 1 1g 2 H 2 SM HAJ ERTH KM VM EVM C2s 27H46 49N13 1409 10 caries granular form RTT DO ILATE ILA Cb SAS
204. WTS contact examination X DEMME DRE postresection thoracoplasty
205. 3 2 Mori QFT 216 20 93 1 BCG QFT 1 9 95 0 5 4 7 QFT 98 20 1 89 QFT 99 BCG 573 QFT 99 8 99 1 QFT 100 4
206. Z Seibert PPD 1 0 05ug 0 1m7 tuberculin aller gy MRM E ZODRA IRZ FI TORN PPD PPD BCG EERE PRT LIV active substance s of tuberculin PIAUVIVY YR HUE active pro tein antigen of tuberculin
207. 10 INH SM PAS RHE PZA INH REP PZA SM EB 2 INH RFP 2 EB 3 4 2004 REP INH PZA First line drugs a SM EB First line drugs b KM TH EVM PAS CS Second line drugs 3 10 Thi SF VM CM 4 adverse reaction of antitu berculosis drugs Kx Ky Kz induration
208. KEI gt Bl AMIE 3 4 5 BCG A ADA adenosine deaminase ADA ADAi T ADA 2 ADA PERIZIE ADAi ADA 50IU 7 PERE OD WAH CS LATS T ADAz adjuvant a7 V
209. OF 82 BRE OIA PER PPR periodic treatment progress report DOTS DOTS T E hypoxemia O COPD
210. 2007 X HIV 20 BCG 30mm 10mm 15mm 5mm BCG 40mm 30mm 20mm 15mm chemotherapy
211. QFT 1 18 72 95 49 88 48 85 95 75 96 92 12 13 QEFT 54 81 95 69 90 78 OFT 80 90 QFT
212. relapse X X EORI cell mediated immunity CMI cel lular immunity T intracellular parasite intracel
213. A 1 B l C 2 D 3 DARK VE dihydro streptomycin DHSM SM CHO H 2 CHzOH 1971 eiprofloxacin CPFX 1 0 3 0 6g 2 3 O lt 6 Qian N HN N N HCl H20 epitaberculosis gt rEYAVIU YA low virulent bacilli INH DEF Rd SMM HABE EC eS EG WHA
214. Bi WHET AS X tuberculous peritonitis lt ARAROA E L TILE A BLOB KO Ne RIB survey on tuberculosis registry 1961 1973 78 83 2000 10
215. EB X M EN TIER OTE E ERLI ODE b empyema cavity reducing opera tion SS Wish gt Heng Figs Au Se Ha Gh removal of empyema sac VARCHAR ATE TT
216. home oxygen therapy HOT galopping tuberculosis BAIL ABC TEED RES ARETE DDS FG PEAY amp IE 106 microtiter method 0 2m7 Mycobacterium daily administration RFP INH SM 2 3 gt Te REE
217. retreatment 1 2 cytokine IL 1 IL llorl2 IFN TNF CSF
218. 35mm 570mm 100mm indirect drug sensitivity test p KERSE CORTES lintectiousness index of TB cases 10 0 1 9 9 ER 0
219. 0 35I1U mL TERR CHA IENE IFNN IENC IFNN 0 35IU mL T IFNM IENN 0 5IU mL 4
220. Mavium complex skin tuberculosis A OSCR BE encapsulated caseous lesion
221. 89 gt ity Ai surgical treatment of thoracic empyema WEL BASH EILA Si ORE A
222. MERKS 8 40 fw tubercle bacillus pl lli Mycobacterium tuberculosis ML a M tuberculosis M bovis M microti WW M africanum M tuberculosis 1882 Robert Koch 1 4m 0 3 0 6um 2
223. criteria for drug resistance DRAR PE drug resistant bacteria bacilli ii RAK Mi KERA 75 infection with drug resistant bacilli RAMPER ESR Oni ko CHT drug resistance test fetal infection
224. BCG ulcer caused by BCG inoculation BCG BCG 4 6 S SIM ESBS BLUMER LES a gt pay RHE BCG technical assessment of BCG vaccination BCG 3 12 16 18mm SHEDE IINE EZIAN Y YI DRS EHE
225. DC Ae ASEAHFBEL pleural callosity callus BEWERKBARE REE ai Nh Ne a pleural adhesion 2 ORM PRAM CE DT 36
226. DTH T DTH DTH delayed type reaction thioacetazon Tbi 1946 Domagk 1952 ak CHsCO NH CH N NH CS NHz Tibion DFAT ULITY typhobacillosis
227. 24 48 1907 CONHz Bi unstable non cavitary type MICH S DEK 702 2 2 1 combined strep tomycin SM DHSM
228. 93 WOPKE RR apical disposition a PE DAL AG IRIS COT OEE Oz pneumonectomy gt lili ae Batt apical lung field X pneumonectomy pulmonary arterial pressure 25 30mmHg Fk ihe HH 8 10mmHg 12 16mmHg 1 5 1 6 pulmonary angiography PAG
229. Hi 48 hemothorax hematothorax AGRA hematogenous pleurisy hematogenous hemic spread dis semination W
230. RARER OFT 8 10 HAD QFT 8 URGE QFT 8 QFT
231. post Primary initial focus L secondary complex D DREH ERE CARI DRUK amp Ze V double strain infection do
232. E Mycobacterium gt SLA mycolic acid o C 14 24 MBO non responder to health examination initial drug resistance
233. National Tuberculo sis Association Nation al Tuberculosis and Respiratory Disease Association NTRDA 1968 1973 American Thoracic Society ATS Patter closed cavity gt 22H O Tee closed healing patient s delay 2 2 3 1 70 EL OIE
234. HS pH 70 WE REKORD ADNA gt HEE calcium deposit erythrocyte sedimentation rate ESR KIE EL Westergren 1 10mm 15mm inoculation tuberculosis T
235. 1974 2003 2006 1644 1 300 A international Union Against Tuberculosis and Lung Diseases IUATLD TY Fo HTP D 72D KUTA BVO EBH 1920 80 2 000 1952 B 1986 IUAT National Hospital Organization 2004
236. 24 26 28 30 35 50 O Oz 105 Boyden s hemoagglutination test ventilator JE ME Oz
237. ZES Ohi TERNE v DRIED BATE QMARO RAKES k SHED UE SHARE bronchiectasis HRCT Cb HAR CLT Mycobacterium avium M intracellulae MAC WD M fortuitum M chelonae M abscessus MAC
238. 1 0 45g 2 INH DR CHs CHs O CH N N N CHs OH LY streptomycin sul fate Z LZ KYA YY gravitation abscess DIED AEA Y WILETHE THIER provision of treatment and education for tuberculosis children 21 HBR O
239. 5mg kg HMS INHG IP CONHNHz N medical facility mandated for diag nosis and treatment of tuberculosis primary infection type atypical mycobacteriosis M kansasii PRAJE primary tuberculosis 14
240. ASHE ofloxacin OFLX 1 0 3 0 6g 23 19 HY DARRAR SILEF Y ambulatory community DOTS DOTS
241. 70 DOTS 85 IUATLD WHO 6 2006 Global Fund to Fight AIDS TB and Malaria Global Stop TB Plan WHO Stop TB Partnership H high risk group n JARAT HIV human immunodeficiency virus infection BREET AEE HIV I II DORRES HIV ELISA
242. b d i 1 WDA UL WAY IV ETL IV AY VIE IV ii IMV ii e i GRO ii GAR ili V 118 AN 613 MOOD 1 D 1 I ECA A
243. IERIE i REO sputum examination DARET NZA AMIE LEM FE IRES 1 SI PEL 5 ee DHT pM gt P SAE PoE EA sputum cytology
244. 2 5 Schwartzman DIC motivation for taking treatment H openly healed cavity clean walled cavity Zh OBIE OAKKE ARES
245. 140 70 60 000 46000 soa medium L KIRJA Y Vrye AX osteitis BCG bone and joint tuberculosis osteoar ticular tuberculosis WS HED 5 OP OMT HEIR Ic KY HOSS DC S SIRI GENRE 274 WENEN A SNSZCES HSM
246. Lot 6 1 post vaccination health monitoring Immunization Law BCG preventive chemotherapy chemoprophylaxis 5 DALY ZY SARE Rasmussen s aneurysm ZERE lt FES HWA IL ZEAE OD fee HE BEC k o CARMA ICTS D AHIR BELL L
247. RE DEF SDC tacheostomy LAO PE VENER IC k ARIE KE WF previously infected person 31 X GRA
248. teat ment of atypical nontuberculous mycobacteriosis JERA EDU AE M kansasii M szulgai MACHETE EAH MAC ATS CAM REP EB3 SM 2 3 10 12 1998 ATS SM KM 4 M kansasii RFP INH EB TH SM CAM LAL PZA M szulgai REP EB SM TH Mfortuitum ke M chelonae MAC
249. 73 rapid grower EAM TEA RAZ Mefortuitum M abscessus M che oge Hi 25C 37 1 3 1 decubitus postero anterior view radiography ERE EWL T X accelerated reaction
250. MIC EIS 1 negative conversion of bacilli ER AARE I lt Wa ETO o TOMBE OPM 37 RRRA WEED KR 1 k bacilli negative conversion rate MR SV we gt TEE open negative cavity HE 6 4 tension pneumothor
251. 21 classification of pulmonary tuberculosis des ignated by the Japanese Society for Tuber culosis GAKKAI classification 21 classification of pulmonary tuberculosis on X ray findings 91 clean walled cavity 63 closed cavity 105 closed healing 105 closure of bronchial fistula ss 31 COz narcosis 86 coagulated egg medium 112 coagulation necrosis 34 cohort analysis 55 cohort meeting 55 cold abscess in chest wall _ 35 REIR 25 cold abscess IRZ 114 collapse therapy 37 collapse therapy of the lung 91 cold abscess colony 55 colony 62 combination therapy 105 combined streptomycin 102 compensatory emphysema 75 compliance 56 computed radiography CR 56 computed Ne GE 27 a concentrated ne smear 61 congenital immunity 72
252. nosocomial infec tion control BCG D Y hospital DOTS DOTS flu syndrome HESE REP
253. Th1 Th2 MURE Th R S INH Th1 Mavium complex Th2 S 5S RR Th2 Th2 CD4 BRL Th1 T M TAHOO DEET 2 T gt target point Tibion a gt y TFy bh RA Yb TBGL Tuberculous Glycolipids aFATRLITY tube drainage TBGL ZAA k URRIRA ORUBE amp trehalose6 6 dimycolate TDM trehalose 6 mycolate 2 3 diacyltrehalose phenolicglycolipid ELISA
254. X lobar shadow Araya pulmonary fistula SAREN k chalky degeneration lobectomy F CNS OMe AIL
255. raphy CT SC XR CORA eS X computed radiography CR X X
256. y ELISPOT IL interleukin INH isonicotinic acid hydrazide isoniazid INH CNH inactivation type INH NWS MiMCORBEIL INH INH isoniazid ISTC international Standards of Tuberculosis Care D gt HTL REO EERIE NE IUATLD international Union Against Tuberculosis and Lung Diseases gt EELS ANB YG JICA J JICA Japan International Cooperation Agency K Kirchner s medium gt ver Heh KM kanamycin maArVAYY Koch s phenomenon gt a y RHR L Langhans giant cell DIYA y ABRAM L wenstein Jensen s medium L J m
257. BEEE EE L onset of tuberculosis following pri mary infection GY WEERT 20 primary lymph node lesion Ii A RE ERE E 1 Zev initial aggravation
258. TB G 5 1 R RFP 0 2 A adjuvant ml 3 Ae LEADS 4 5 WESDE S FAROL LTY L 6 AR 1 1 2 2
259. CHS DEROSD ZOO PRA WARAY O DNA DDH arterial blood gas analysis arterial oxygen partial pres sure PaO gt LY AT A AT arterial oxygen saturation SaO gt LILA A AAT BY ARO BRAG ADEE arterial carbon dioxide partial pressure PaCO translucent area X X deletion from TB register 3
260. Hugh Jones degree of dyspnea 5 I VE II ME 1 1 6km 707 NVE 50 45m VES X ray classification of pulmonary tuber culosis NTA istandard therapy RFP INH PZA SM EB 4 2 RFP INH EB 4
261. NALC NaOH 4 NaOH membrane type oxygen con centrator One EY EDT Sie O O 40 10 INAKI E EA SEDOT macrophage promonocyte monocyte II
262. 1 3 acquired immunity EWA family household contacts examination 17 2005 0 5 0 026 20 1 family infection L 14
263. 3 metabolic acidosis metabolic alkalosis compensatory emphysema acquisition of drug resistance EAD COR RAIS OW TAS
264. Ey RIN cervical lymph node tuberculosis tuberculous cervical lymphadenitis T E MELE PES IREA lt REIL TIAE 41 gt cervical lymph node biopsy SEB SRNA
265. QFT ESAT 6 1995 CFP 10 1998 T gt IFN QFT KOR ESAT 6 7 CFP 10 6 IEN 7 733 ELISA Mycobacterium tuberculosis oojs AL africanum A kansasii M marinum M szulgai M flavescens M gastri M epyze M bovis BCG
266. 1990 SOC 1970 0 157 SARS 30 artificial pneumothorax 1888 Forlanini 1935 BL TK PHB ABEL EO g mp ii FY EE artificial pneumoperitoneum HS
267. 2 2 5 3 3 4 intestinal tuberculosis MAA E OME MAA Le a extensively drug resistant strain XDR ZAMEK RTE S BIA VA YY WHO CDC 2006 acoustic auditony disturbance 5 VM KM SM CPM EVM
268. 81 active substance s of tuberculin 81 active tuberculosis 22 activity classification 22 acute empyema pyothorax ai HEN 32 acute respiratory distress syndrome ARDS 32 adequate treatment 83 adherence 12 12 admission or a of tuberculosis patient adrenal corticosteroids aK 103 adult respiratory distress syndrome adjuvant 144 68 adult type tuberculosis 68 adverse effect of BCG vaccination BCG 2 adverse reaction 102 Hf adverse reaction of antituberculosis drugs 50 adverse reaction report 103 air fluid level 36 air fluid level 87 airplombage 16 airborne infection airborne infection oie alveoler pattern Jli ale a alveolus pl oli ambulatory treatment pene Aa 1g ambulatory community DOTS 19 American Lung Association ALA 104 anergy annual ea on estat
269. BEA Dict double barred christmas seal 1904 1923 1952 adrenal corticosteroids
270. PZA RFP INH SM BB 3 6 RFP INH EB 3 D 3 disease status unknown 1 6 opportunistic infection HOW DS BRP TARWVEVA
271. DERA DITOR iT treatment success DOTS 2 ME Lt 80 drop out from treatment abscond from treatment gt ie wy Ziehl Gabbet s stain ing w D Z N Ziehl Neelsen s staining 1882 Koch
272. EPCRA CHIE Gf3 HE I 2
273. istration Japan Anti Tuberculosis Association JATA 1 1961 1987 47 1939
274. prevalence of infection BCG BCG 2005 10 0 4 20 1 4 30 3 3 40 6 7 50 14 9 60 35 5 trachealbutton HS
275. 1 bb X 1 EK HOHE X hanes cation of atypical nontuberculous mycobacteria case registration card noninvasive positive pres sure ventilation NPPV NPPV UC MGIT QR CHS CL OER OIF WAATA O E ORI PNB
276. 99 treatment of nontuberculous mycobacteriosis 99 treatment required 111 treatment standard 14 80 treatment with fresh air and bed rest 74 tube drainage 34 tubercle bacillus pl lli 42 tubercle 44 tuberculin allergy 81 tuberculin non reactor after repeated BCG vaccinations 86 transudate treatment success tuberculin 80 tuberculin reaction 80 tuberculin reaction 81 tuberculoma 45 tuberculosis advisory committee 46 tuberculosis allergy 42 tuberculosis associated with pneumoconiosis 67 tuberculosis bed 47 tuberculosis control chart 42 tuberculosis control law 48 tuberculosis death rate 44 tuberculosis emergency declaration 43 tuberculosis epidemic 62 63 tuberculosis in children tuberculosis in the young adult sl tuberculosis infection
277. X bimodal distribution BCG E 0mm 30mm 2 87 RERE 15 BCG
278. EEA silicosis EK 10 BP BE X X mp ELM RAY TEAK silicotuberculosis PEM Eh Hilt l
279. ME Tb FEDA A CSNHz N CHzCHs T epituberculosis lA SCALIA Sr X lt THY long term follow up results HAT enviomycin EVM 1968 TUM N R OH TUM O R H O ll CHe CHz ga gh CH2 C NH H NH R NH 18 VA Streptomyces griseoverticillatus var tuberacticus VM 1975 9 en VM 1 1g 3 2 3 SM KM
280. kanamycin KM 1957 Streptomyces kanamyceticus 1961 1 1 2g 2 2 1 1g 1 3 VM EVM CPM CH2NH2 OH OH NHz OH HzSO4 ial o HO OH NH2 CHzOH 22 nower lung field X 4 lower lung field tuberculosis RI X
281. HB venous admixture mixed ventilatory impairment elimination IUATLD 100 e i S Ei a 1 ACOs 1 reinfection tuberculosis computed tomog
282. 65 WE SNC LIDS RELLA J fungus gt I DT AK VW AJE renal tuberculosis THAD EM ica LT RK CT emerging infectious disease WHO 20
283. NEE tuberculosis of female genital organ TTP primary inoculation vaccination BCG 6 BCG BCG DARK BCG RE visual disturbance dust infection
284. New Terminology of Tuberculosis The Japanese Society for Tuberculosis 2008 Published by Nankodo Co Ltd Tokyo 2008 bb 2007 2008 4 2008 4 BAR i A E R Ont NTT mee ye x 1990 DOTS
285. OPF IPF X apicolordotic view radiography XIE T A I Ds TAS EA IC 25 30 NS CT pneumonectomy
286. RE 1953 1973 5 1961 1987 1998 oxygen uptake VO O WS 250m Os o
287. BCG humoral immunity 17 B T T B IgM IgG liquid medium MGIT ers MGIT liquid vaccine BCG Calmette
288. GE NAP NAP BACTEC BACTEC 12B BACTEC 12B Growth Index GI 5ugNAP L 37C 1 2 5 L GI GI BACTEC NAP 5ug m7 Mid dlebrook 7H11 7H9 NAP
289. Ek 20 4 HW L TUT TAY PEAZENS ABC 2 3 4 JRRD e PAT DERE ARA E
290. X air fluid level strong ly positive 10mm intensive chemotherapy EREKE SM ORF EB ARTI AT OKERE 4 RFP INH BCG local reaction BCG 2 4 1 3
291. urinary tract tuberculosis EBB annual risk of infection ARI ARTI 1 BCG 1968 1950 4 11 1980
292. 1 Hi AK Cd A DEK aestroyed lung ERKEN E 7 LS EEE high prevalence area periproctal abscess ERT GE senile tuberculosis
293. 113 n eae sanatorium O sanatorium 1914 2004 U nous spread dissemination HPI D gt 6 MERU YOST A CLAS A Wy drug lymphocyte stimula tion test DLST
294. 10mg BMH il 103 acces sory reaction of tuberculin test PARMA Y adverse reaction report
295. PER ECHS BMRC ATS DLD drainage bronchus HERE XE DV EREK BS vide 2 RFP 22 PALA PZ prevalence of disease
296. annual i on es 88 annual risk of infection ARI ARTI 88 Anti tuberculosis Women s Society 48 antibiotics 51 antitubercularagent 50 apical disposition Mii aa 93 apical lung field ili EF apicolordotic view a IRI 93 arterial blood gas analysis 83 arterial carbon dioxide partial pressure PaCO 83 arterial oxygen partial pressure PaO 83 arterial oxygen saturation SaO 83 artificial pneumoperitoneum 66 artificial pneumothorax 65 asymptomatic pathogen carrier 108 atelectasis 108 attack rate 97 atypical mycobacteria 98 atypical mycobacteriosis AM 98 auditony disturbance 79 avian bacillus 85 axillary lymph node swelling Meg Y Y 7 fii IEK BCG 17 B bacillary dose 38 bacilli negative conversion rate W KIEZ on 37 bacterial pneumonia 56 bactericidal action 58 bactericida
297. gt 0 5 2 LDH LDH gt 0 6 3 LDH gt LDH 2 3 b GE BUMS MME 66 exudative reaction BANC
298. 17 ethionamide 1314TH 18 examination of laryngeal swab 51 exogeneous reinfection 19 expectoration 76 extensively drug resistant strain XDR 79 extensively drug resistant tuberculosis XDR 12 extraordinary health examination 82 extrapleural plombage SGN 35 extrapleural plombage 35 extrapulmonary tuberculosis 90 exudate thi 66 exudative reaction 66 F false positive 34 family contacts examination 21 family infection 21 far advanced tuberculosis 62 far advanced cavitary type 52 fetal infection 75 epituberculosis FEVi 1 14 fiberoptic bronchoscope 77 7 30 fibrocaseous type lesion 71 fibrosclerotic type lesion 71 first line antituberculosis drugs 149 14 fistulography 114 flu syndrome 15 fluorescence microscopy 40 focal emphysema KIRKE 73 follow up examination 28 follow up required
299. COPD COPD NPPV atypical mycobacteria JEA PEDRA human tubercle bacillus human tubercle bacillus Mycobac terium tuberculosis typus humanus Koch s bacillus gt ity Tal non specific reaction DAVY Y SUBIC BV CARA D Ae A Eee ERARD DMR LPPD E Bio TIERA PEDURR TEC UY y
300. FE tuberculosis allergy WV 24 72 purified protein derivative of tuberculin PPD YN
301. HIV R HOT home oxygen therapy Hugh Jones degree of dyspnea HszRv MERROW Human R R v virulent 5 HszRv HyRa alxavirulent IGRA interferon gamma release assay 7 TB T Spot TB y ELISA
302. Ly SREB LOST C NH CH C NH CH C 0 3 2HzSO4 Nse NH amp CHe fe I OH NH C NH2 NH C CH NH C C C Il Il N H O 0 90 DEY OR vital capacity VC 1 KIRJE lung abscess pulmonary suppuration ACHE PERITE C d PRET Ze D OUCH TR WAER ES OO HS BRERA LSS O SIMBA CIFA TORR X IREK
303. new quinolone compounds niacin test niveau R PT NTA NTA INTA classifi cation of pulmonary tuberculosis NTA National Tuberculosis Associa tion X 1974 NTM nontuberculous mycobacteriosis N95 N95 mask 0 1 10um 10 N N Notresistant to oil R Resistant to oil P Oil proof 95 100 99
304. 3 4 WAIORA O 37 25C 42C CO NS DRIE DEK AEE k NSH STH ETH cuture examination ER 37C
305. YI AK KE BR DAF IVIANATF F adherence anergy T MRK
306. A gastric juice lavage aspirate examina tion BAAR CIF SO ASIE LYS ATIAK 15 shortness of breath breathlessness provision of treatment for the handi capped children 20 liatrogenic HN LORIE O retained remaining persisting
307. NIS te hs 190 13 tuberculosis control law 1951 H 1919 T se X BCG 72 op 2004 BCG MPP 2007
308. 1 IF respiratory reha bilitation Japan International Cooperation Agency JICA
309. 2 tension cavity 37 tension empyema pyothorax 5 ihe VE JIE Jig 37 tension pneumothorax 37 thin wall cavity 96 thioacetazon Tbl 78 thoracentesis puncture CABLE thoracic empyema due to bronchial fistula 31 thoracic empyema with bronchopleural fistu la APERE 111 thoracic empyema without bronchial fistula 109 thoracoplasty 33 target point 758 thoracoplasty 34 thoracoscope 33 thoracoscopic curettage Mesi F FEMA 33 thoracoscopic empyema cavity curettage ESE P WHORE EMC A 33 thoracoscopic lung biopsy lt 33 thoracoscopic surgery 33 thrombocytopenia 48 thymus 35 Tibion 78 tomography 77 total delay in case finding 97 trachea 28 tracheal button 31 tracheobronchial tuberculosis 28 tracheobronchoplasty 28 tracheostomy 31 transbronchial lung biopsy TBLB 39 translucent area 83 115 treatment of atypical mycobacteriosis
310. Hi 99 BiPAP bilevel positive airway Pressure IPPV intermittent positive pressure ventila tion PS pressure support NPPV DBD
311. X BEAR AAT drainage of pus NEWER PSC ARLES Z MN BNE HERT 3 OP RIPE ECEE k o THER OBERE gt iia pulmonary nocardiosis Nocardia asteroides T DRE SoM RK CHS
312. 46 tuberculosis like 92 tuberculosis low prevalence country 82 tuberculosis mortality 44 tuberculosis of bladder 105 tuberculosis of eye 23 tuberculosis of female genital organ 65 tuberculosis of male genital organ 7 tuberculosis of rib tra UTA 115 tuberculosis of the knee joint JAPA ITA 60 tuberculosis prevalence survey 44 tuberculosis sequelae 44 tuberculous anal fistula 45 tuberculous cervical lymphadenitis 4 8 Y 41 tuberculous coxits 52 759 Tuberculous Glycolipids TBGL 11 tuberculous granulation 45 tuberculous meningitis ZERIKA 45 tuberculous otitis media 78 tuberculous pericarditis 45 tuberculous peritonitis 46 tuberculous pleurisy 45 tuberculous pneumonia 45 tuberculous spondylitis HEZ Y 1A 70 tuberculous thoracic empyema 45 two step tuberculin skin test 87 typhobacillosss 78 U ulcer caused by BCG in
313. miror camera T atelectasis X BF ELT MES Hk JE AREK PAIK k TEMES OUTFIT OPER RIES KS HORE Ze EDS CT MRI FA
314. 84 immune reconstitution syndrome IRS 109 immunity in tuberculosis _ 47 Immunization Law 111 immunocompromised host 109 immunodeficiency 109 impaired pulmonary function 82 inactive 102 inactive tubeculosis 102 incidence of disease 112 index 60 indirect drug sensitivity test 25 induration 50 infection with drug resistant bacilli 75 infections caused by M avium complex M avium complex 7 infections caused by M fortuitum M fortui tum 8 infections caused by M kansasii M kansasii 8 infections caused by M scrofulaceum M scro fulaceum ti 8 infections caused by M szulgai M szulgai ie 8 Infectious Diseases Control Law 26 Infectious Diseases Control Law 26 infectiousness index of TB cases 26 infiltration 66 infiltrative shadow 66 INH inactivation type INH 5 initial aggravation 64 initial chemotherapy 63 initial drug resistance
315. E R fal Rey Ale FR KA Rey TH X RI fa 0 RAK RE 1995 2001 3
316. Ei ERNE CO AED AH E RFP 3 percutaneous inoculation BCG LT 1967
317. OFT RARR QEFT OFT QFT ESAT 6 CFP 10 QFT QFT 12 OFT
318. AIRED NTP ABEL CT 96 thin wall cavity 2mm persister mp FFL IR Al vital capacity VC PAS total delay in case finding
319. BAPE OARS eg HL a CHB DK EMKA PHC MATEN ZS infiltration X DRESS FOB L CRLF BK infiltrative shadow HOMEOKS S amp H OME ORV WARY We Rae OO Hi oR dIE CI caseoinfiltrative type lesion ET
320. microtiter method z ZUJA Jik Middlebrook Dubos hemoagglutination test D gt IEVIVY 7 gt FaRA NID Millennium Development Goal 2001 BEC 1990 2015 mirror Camera MMR mass miniature radiophotography DERE MRI magnetic resonance imaging mD AIEG mR Much s granule gt A 7 7 muramyl dipeptide DAT IMVIUNATFF M bovis mycobacterium A DAA RRA M avium Mycobacterium avium MIRRE OPO MEE GEJ M intracellulare M intracellulare M avium intracellulare M avium complex MAC SOR
321. 2 PE chronic empyema pyothorax gt isha chronic obstructive pul monary disease COPD COPD Mantoux test Mantoux LEC 0 1m 48 ml TER IIS 27G
322. 23 DARRAR LC HERE WR E RA ventilatory failure rod form HALA OPAL SF 4um 0 5um ROR CdS WERA ocular tuberculosis tuberculosis of eye ROA
323. 72 congenital tuberculosis congestive heart failure 16 contact examination 70 contagious parameter 27 continued home visit 40 continued treatment 40 control indices of tbe 28 cor pulmonale 92 cord factor 54 cord formation 54 corrective thoracoplasty 106 correspondence to an attending physician 13 costal caries Wy LA 115 costophrenic angle 115 cough 69 criteria for drug resistance 75 criterion of tuberuclin test reading 81 cross resistance 50 CSF examination 70 cultivation 95 culture examination 95 culture 95 curettage under thoracoscopy 33 147 cyanosis 78 cycloserine CS 56 cystic shadow nea ae cytokine cytology of pleural fluid fs on 34 D daily administration 106 danger group 83 decortication 94 decubitus postero anterior view radiography a
324. ADA 50IU 7 60mg d7 HOR 10 20 25 75 D X 45 CT tuberculous anal fistula mp LE Je BH es tuberculous pericarditis LRA BSED a WEZ WALA tuberculous meningitis MS
325. DWAR DESK POUR ti pleural fluid examination 34 PERISH amp WEF ADA cytology of pleural fluid HAVENT amp RE doubtful reaction reactor Y 5 9mm 1995 9mm
326. IgG RE 85 94 96 ae transbronchial lung biopsy 77 T jr lymphocyte T cell MP OD Hi SEM ASW CAME major histocompatibility complex MHC CD3 B BITA T helper T cells Th T cytotoxic T cells Te VATS CD4 CD8 4 Th 2 inter leukin 2 IL 2 y inter fewron y IFN y ympho toxin LT Th1 IL 4 IL 5 IL 6
327. WIC Ae Bie L D pulmonary segmental resection 2 5 1 1960 1 2 pulmonary tuberculosis 80 1996 Z NN
328. 1 1 fibrocaseous type lesion MV C 1cm PRA SIPEG aI gt 1 fibrosclerotic type lesion
329. DOTS pots Japanese version 53 14 15 DOTS 2004 1221001 order of hospital treatment 8194 20 264 H hospital treatment admission or discharge report of tuber culosis patient
330. LOA 200 ld 2007 4 n TRAK HL
331. Th2 Thl Th2 1 V VATS video assisted thoracoscopic surgery ventilator Venturi s mask VM viomycin W WHO World Health Organization MERE X XDR extensively drug resistant tuberculosis DEZ ANEA Z Ziehl Gabbets staining D N ANY Ziehl Neelsen s staining F REVAi Z N adjuvant
332. revaccination reinoculation BCG BCG home oxygen therapy HOT 57 O 55Torr 60Torr
333. 1953 Ogawa s medium 1949 NazHPO4 KHzPO4 Wit 100m7 1g 2g 3g 2 KHPO 1 2 3 2 We COMP E NALC NaOH 1953 2000 open lung biopsy
334. 2 INH REP RTA DARE CFE pors conference DOTS DOTS Parmer DOTS
335. 37 88 negative conversion of bacilli new macrolide new quinolone compounds 153 88 newly registered case 67 niacin test 85 niveau 87 nodular shadow 48 non photochromogen mycobacteria 100 non responder to health examination 108 non specific reaction 100 noninvasive positive pressure ventilation NPPV 99 nonphotochromogenic mycobacteria 100 nontuberculous mycobacteria 98 nontuberculous mycobacteria 99 nontuberculous mycobacteriosis NTM J 98 normal life under follow up 111 nosocomial infection control 15 nosocomial infection control fe 42 nosocomial infection RO see 15 Nucleic acid amplification method 20 O obstructive ventilatory impairment 105 occupational therapist OT 58 occupational therapy OT 58 ocular tuberculosis 23 off work required 111 ofloxacin OFL
336. ARDS CD4 HIV RE CHA immunodeficiency B T ARAM y TEEN RE BARS HIV L LIF LIZA AUR IC k o CHASED immunocompromised host HEREFORD PFEZ EY RDK
337. TUY 4 Global Drug Facility DOTS HTV Tb thioacetazone D TEITI TH ethionamide Th rm CD4 Partnership 2 Th1 surveillance Th2 Th1 S smooth s type colony R 5 Th2 Th1 Th2 85
338. lymphatic spread dissemination my lymph node perforation gt lympho hemic hematogenous spread dissemination gt M MAC M avium complex macrophage 77 077 7 Mantoux s test ayy hk MDP muramyl dipeptide MDR multi drug resistance gt Fi iT PEAY MGIT Mycobacterium growth indicator tube 2 yb HIRA FSF Ca L Ze RRS FD gt Co 4 8 1 2 Be MGIT 90 BRITE CHRO MGIT I k V HA OME
339. 64 initial drug resistance 108 initial standard treatment 64 initial treatment 64 inoculation tuberculosis 70 inseparate admission of tuberculosis patients to a general ward 55 89 insufficiency 53 intensive chemotherapy 96 interferon gamma release assay IGRA 5 15 intermittent positive pressure breathing IPPB 23 intermittent treatment 23 International Standards of Tuberculosis Care 42 International Union Against Tuberculosis and Lung Diseases IUATLD 53 interstitial pneumonia WJ PUEIA 24 intestinal tuberculosis 79 intracavitary aspiration 38 intracellular growth 58 intracellular parasite 58 intracerebral tuberculoma APWE 90 intractable tuberculosis 86 intracutaneous inoculation 100 intradermal inoculation 100 104 isolation of source of infection _ 26 isoniazid 14 Ea pi ib a inspissated cavity interleukin IL isolation culture isonicotinic acid h
340. ENS Mi SPE PEER ESCH pneumoconio tuberculosis tubercu losis associated with pneumoconiosis sE accompanying pleurisy pleurisy associated with secondary pulmonary tuberculosis O 20 f TC CBU BEM BULL Ze 0 WEBEL HTK D gt vesicle
341. OFT OFT OFT OFT X OFT QFT 138 MECH SM HEPELAR O T MAC QFT 5
342. WHR S Hic ETM 1 BCG BCG BCG HEU YONGE ar bus BCG method of BCG vaccination SPS RIEL BCG efficacy of BCG vaccination BCG BCG V 1959 1972 BCG 5 83 15 LAL 1968
343. lateral sagittaltomography PAE CAT 9 CT Visit Sauton s medium BCG PPD B gt Wi et He fe miliary shadow 1 2mm postural drainage 1 3
344. obstructive ventilatory impair ment combination therapy 2 3 4 1 uneven distribution of patients AER ERD UC VHB Ventur s mask Os Oz O gt O gt
345. 38 selective health examination 71 semiliquid agar medium 97 senile tuberculosis 52 sensitive bacilli 25 sensitive drug 25 sensitive drug 25 sensitivity test 25 sensitization 24 BRER second line drugs secondary complex secondary infection secondary tuberculosis sequelae due to tuberculosis 44 short course chemotherapy SCC 157 77 shortness of breath 13 shunt 77 sick leave 111 side effect of BCG vaccination BCG 2 silicosis 40 silicotuberculosis FEMA 40 single drug therapy 77 skin tuberculosis 100 sleeve lobectomy 25 slow grower EFW 78 smear positive and culture negative bacil li SPCN RIKE 85 social welfare law for the physically handi capped 67 softening and liquefaction 85 solid medium 54 source of infection 26 special care law for injured veterans 71 spinal caries 70 spirometry 68 spontaneous pneumot
346. A avium M intracellulare QFT 1 IFN 7 2 MEH CACHE S dU 72 IFN y ELISA 2 5mL 1mL 4 ESAT 6 CFP 10 PHA 12 37 12 20 18 50 ELISA HRP IFN y Hi 120 22 5C
347. pulmonary mycosis WA UP bay A AE HS lung infiltration cor pulmonale
348. 72 Me GE 4 4 1 EHR MAIL CW SAR 2 3 RES DL
349. HOMO Tame eK BNC RA ORAA W LUA AERA ELT LILAC BIE L GE RUE SS SP LS gt 2 p RiP airborne infection droplet infection 5um LES 1m diffuse disseminated shadow
350. INH 6 shunt carbon dioxide nar cosis CO PaCO 75Torr pH 7 26 PERK PaCO 80Torr 77 RSC amp RAO WE
351. NN A BB rll 6103 T 7IV1 MM V V DID 7r 1 Op Da eda cee 6 T1 Op 8 HOE 119 A B R
352. VM CPM Oka Katakura s medium 1940 SNe p SFE oka s clas sification 1940 X IW I VE V VI VI MW WRK KA XH XW OH OH 9 CH CH C NH CH CNH CH H C ts A toG Che NH i NH c ch i c a O O
353. mass health examination mass miniature radio photography MMR mass health examination for general inhabi tants ERIRE far advanced tuberculosis IW DARK group infection of tuberculosis tubercu losis epidemic 2 20 1 6 1937 1980 mass health examination mass minia ture radiophotography MMR
354. HIV 6 8 HITV 7 YON FREE PER TA N HIV epidemiological index RREO REER WACK HEALY A 4
355. 30 1 30 138 1 1 2 z 122 6 8 RAO ES jas am Clim we A ee gt lw aOR 0 0 2 1 LEDS 1 ee 6 5 9 1 3 7 8 1 1 8 7
356. JD RBS Le HEU 1 3 2 3mm DRRDRR SND 15 gt I YONGE BCG HEE collapse therapy Kirchners medium 10 PATRIA URIS 7 V
357. V WOU Ze Ce TR H otitis media tuberculosa tuberculous otitis media 1 REFL Hia central necrosis moderately positive 10mm middle lung field X 2 4
358. ak 5 1 z 36 9 22 757 2 36 9 22 757 z 37 5 16 22 3
359. sensitive drug WSN ODED Ch SBD HURT sleeve lobec tomy EPEE multiple puncture method by a tube with multi needles BCG 25 PREC HS KS 0 3mm 9 5mm 17 5mm
360. M avium IS72475 Po RFP rifampicin Robert Koch AS RP radiophotography X RP radiophotography photofluorogra phy IRE radiophotography W RP R rough R type colony Hh LORE Aot ARTUR R R 10 S REER ORIA ANE mS HAR S SaO arterial oxygen saturation gt LTE A RSAT Sauton s medium y p vib Schub exacerbation deterioration
361. X MBCA SH C PMI DEAE DET renal disturbance KM VM CPM SM SM 1 0 75 0 5g KM 1 5 0 5g EB 0 75 0 5g 2 4 apia growers Runyon Wir Cah V 1 3 4 8 WRAY 90 M abcsessus M fortuitum M chelonae social welfare law for the physically handicapped
362. 9 12 monoclonal antibody L BE 100 120Torr CHAK iE 4
363. AAS PAD IVVAIPFR TY epithelioid cell granuloma L TOBE ICO TIL 114 Lowen stein 2 1930 1934 COG 85C Jensen
364. ee ek ADRES 2 OllZ O ALK JX sputum pl ta expectoration RESCH k Ua 5 OAW Mi 273 Ps 5 Mi Mz Pi Pe Ps HOMILY YNZ DNA lgA MAKE A 5 1S BE shortcourse chemotherapy SCC RFP INH SM INH PAS 2 3 RFP INH 6
365. 0 1 1985 0 01 1 4 DRA EEE class 2 infectious disease annual report on registration 1 5 SARS 88 IRI empyema of the thorax pyothorax MEP AIRI REOR M iD A BN II ES 2 J HH
366. 2 FES 3 1 PILI TT 4 y Vax N 1ck 2 N95 N95 1 1 va 2
367. 65 dysequilibrium 104 E early generalization 72 efficacy of BCG vaccination BCG 2 egg medium 112 eighth cranial nerve disturbance 75 elevation of the hilum 95 elimination 55 emerging infectious disease 65 empyema cavity reducing operation Jay 89 empyema of the thorax IRJ 88 empyema related lymphoma Jk PIE vy 89 encapsulated caseous lesion 100 endocrine disorder 85 endogeneous reactivation 385 endoscopic examination 85 endoscopic surgery 85 endoscopy 85 enviomycin EVM 18 enzyme linked immunosorbent assay ELISA ELISA 4 epidemiological index se epidemiological model 17 epithelioid cell 114 epithelioid cell granuloma HE 114 epituberculosis 18 61 erythrocyte sedimentation rate ESR 49 erythrocyte sedimentation rate ESR 70 erythrocyte sedimentation rate ESR 70 ethambutol EB
368. EES pI gt ABLE standard of tuberculosis med icine Imternational Standards of Tuberculosis Care DOTS TBCTA CDC 42 WHO 2006 17 nosocomial infection control tuberculosis control chart
369. X RFP INH RFP 277 6 meag A PZA SMER INH REP E 6 9 INH RFP SM EB eae ee SM 2 3 2 AlMEB 2088828 64 3 3 6 primary tuberculosis RRO FH primary complex
370. emi MER J RFP WENE i B mit ee ATR OE EB RETR ga Eb Et RAX TH fe e BH Bb m CS BH Hone a x eb UBM PZA lt FH PKS pd AIRI 125 obs FS
371. 1949 1967 doctor s delay KZ y FAVA newly registered case BSN LK 67 HS pneumoconiosis
372. 736 OFT 45 5 7 1 33 0 7 45mm BCG 45 QFT x 0 87 8568 k 0 87 BCG QFT QFT
373. BE on Re MMS 2 R Orei OME DARA DML PML REE I 5 lintra cavitary aspiration Monaldi s drainage X FW EMAL
374. N 2005 direct drug resistance test HL EEO iy a HB direct method surgery
375. R 5S M avium complex M avium com plex SARK SREE sg MAC LCS MAC ATS CAM REP EB 3 SM 2 3 if 10 12 1998 ATS SM
376. RER SEL 1947 EFL extrapleural plombage pleural biopsy pleural calcification
377. cavernostomy 39 cavity healing 39 cavity with sclerotic wall 50 cavity 38 cell mediated immunity CMI E58 cellular immunity 58 central necrosis 79 cerebrospinal fluid 70 cervical lymph node biopsy FR AL cervical lymph node tuberculosis Y X 41 chalky degeneration 96 chemical constituents of tubercle bacilli 43 chemokine 49 chemoprophylactic case 107 chemoprophylaxis 20 chemoprophylaxis 111 146 chemotherapy 20 childhood tuberculosis 63 childhood type tuberculosis 63 chronic bronchitis 107 chronic empyema pyothorax 18 PEJA 107 chronic obstructive pulmonary disease COPD 107 cicatricial healing HRPE RE 97 ciprofloxacin CPFX 60 cirrhotic reaction 50 class 2 infectious disease 88 classification of pulmonary tuberculosis des ignated by the Japan Research Committee for Chemotherapy of Tuberculosis GAKKEN classification
378. 100 gL 30 OFER SO u LEERME 5 450nm 620nm 650nm 2 Cellestis IFN y TFN y 30 2 1 1 4 TEN y ESAT 6 CFP 10 IENE IFNC BHEIRINN
379. hilum LIES VAA X WDR SEMA USERS K V Mi PSB X hilar shadow X 2 4 7 9
380. 113 113 doctor in charge of case management Cd 28 doctors delay 84 67 direct vaccination dissemination dissemination doctor s delay dormant 85 dosage 103 DOTS conference is 84 DOTS Japanese version DOTS 87 DOTS Partner 84 double redness 87 double barred christmas seal 103 double barred cross 102 double strain infection 87 doubtful reaction 34 doubtful reactor 34 drainage bronchus 110 drainage bronchus shadow 73 HEMT 93 80 drainage of pus drop out from treatment drop out 76 droplet infection 101 drug allergy 110 drug lymphocyte stimulation test 113 drug resistance test 75 drug resistant bacilli 75 DLST 148 drug resistant bacteria 75 110 drug sensitivity drug susceptibility test 110 drug taking rate 103 Dubos medium 83 dust infection
381. I I I A BABE U VINER caseous lymphangitis RACES Bey PERC SES HONE caseous lesion p DR EIRA caseation gt HC AGERE caseous mass cageous bronchitis T caseous degeneration 27 doctor in charge of case management follow up examination 53
382. 0 7IU mL 50 OFT 5 12 135 1 IFNe IFNn IFNc IFNA aR 0 35IU mL 0 1IU mL 0 35IU ml ERORE ZEL 0 1IU mL FNE IFNN IFNo IFNa 0 35IU mL IFNw IFNn 0 5IU mL QFT
383. 111 forced expiratory curve 85 forced exspiratory volume in one second FEV 1 14 forced vital capacity FVC 85 freeze dried vaccine 83 fungus 65 further examination 69 G Gaffky Gaffky scale galopping tuberculosis 22 22 106 gastric aspirate examination 13 gastric juice examination 13 gastric lavage examination 13 generalization of tuberculosis 71 generalized BCG itis BCG 71 genital tuberculosis 68 Global Fund to Fight AIDS TB amp Malaria tt 69 grade of bed rest and exercise status 13 granular form 23 gravitation abscess 113 group infection of tuberculosis 62 group infection of tuberculosis epidemic 4 62 guidance on daily life 68 guidelines for mycobacterial examination 43 H health examination 49 health examination in the enterprise 59 hematogenous 48 hematogenous pleurisy 48 hematogen
384. 2000 2006 2007 R L lipid of tubercle bacilli 0 0 A B C D BOKPE AD D W DE ERAMU b dD SH EA F AA Y ABA tuberculosis sequelae sequelae due to tuberculosis polysaccharide of tubercle bacilli
385. 9 CHA 3 1 2 1 737 SEAN HOE
386. Am ARR ai HERE PAS TR ne FLU eee EB EOE ma ioe me 7R TH a SF 3 ie mR TR cs TEUR oe RE TR PZA mi SET 124 BE ey 3 serm ZARE zote aoa a G BREE sm PRS SER aaao Bt KM SES AMER EVM 388 GES ies eas ak a ORM INH en Be Cushing A x wcuaeasym b mH 3 PAS ee OF m BERDE DABE mZ Mint D amece BECHS 7m WEKE haa Tal BEE ERR
387. IPPB IRS ISTC oF forced vital capacity human immunodeficiency virus home oxygen therapy interferon gamma release assay interleukin isonicotinic acid hydrazide isoni azid intermittent positive pressure breath ing immune reconstitution syndrome International Standards of Tubercu losis Care IUATLD International Union Against Tuber JATA JICA KM LPT MAC MDP MDR MDRTB MGIT MHC MIC MMR MRI NAP NPPV NTA NTM OFLX culosis and Lung Diseases Japan Anti Tuberculosis Associa tion Japan International Cooperation Agency kanamycin lung physical therapy Mycobacterium avium complex muramyl dipeptide multi drug resistance multi drug resistant tuberculosis Mycobacterium growth indicator tube major histocompatibility complex minimal inhibitory concentration mass miniature radiophotography magnetic resonance imaging p nitro a acetylamino hydroxy propiophenone noninvasive positive pressure ven tilation National Tuberculosis Association nontuberculous mycobacteriosis ofloxacin OT PaCOz PaO PAS PCR PD PEEP pH PPD PPM PPP PPT PT PZA QFT RFLP occupational therapycoccupational therapist arterial carbon dioxide partial pres sure arterial oxygen partial pressure para amino salicylic acid polymerase chain reaction postural drainage positive end expiratory pressure ventilation hydrogen exponent purified protein derivative private p
388. REC dH 0 10 15 1mm 3 4 YER tana MEDED 37 38 Fi pHIL6 8 7 0 MGIT KPO A d MGIT T 2 WFE E 3 8 R S 5 5 DREK H e NEVA D gt S P
389. digestion decon tamination procedure HRAD A Z EIR decontaminant NaOH WED DIRS 5 CDC N L NALC NaOH 2 DNaOHE decontamination L NALC We POR NaOH
390. tuberculosis bed immunity in tuberculosis T 2 IL 2 MAF Oy
391. 0 5g IR ROME HzN oj O re emerging infectious disease WHO BEC 20 1990 1970 F R minimal inhibitory concen tration MIC TOBE HEK CORR TBRL ug ml
392. 7 20 4 OFF a 1992 3 2001 5 2 2
393. 88 pyrazinamide PZA 102 Q QuantiFERON TB QFT TB 39 R radiography 79 radiophotography RP 25 Ranke s classification 112 ranking of causes of death 59 73 rapid growers 67 Rasmussen s aneurysm ul re emerging infectious disease PD 57 rapid grower 156 reactivation 57 regional differencem 78 84 registration system 24 regular drug taking 32 reinfection tuberculosis 56 reinoculation 57 relapse 58 relative risk RR 73 remaining cavity 13 removal of empyema sac _ 89 renal disturbance 67 PERAK 65 registration rate renal tuberculosis respirator 66 respirator 114 respiratory acidosis 53 respiratory alkalosis 659 53 52 respiratory failure respiratory function test respiratory rehabilitation 53 respiratory system dysfunc
394. DP 13 2 1 control indices of tbc WRAEK SUE trachea RLS 6O 7 SHED Fes S CURE IC Baise L U FIED We AKT E RRR O VST D gt 5 Ze 10 15cm 4 5
395. HO HaCHN OH 1 2HzSO4 o Ri CHO Rz CH2OH Re OH HsC Ri spirometry guidance on daily life E 68 FRO EMO bacteriostatic action A EB genital tuberculosis adult type tu
396. KM 4 X M kansasii RFP INH EB TH SM CAM PZA M szulgai RFP EB SM TH Mfortuitum ke M chelonae E MAC M bovis bovine tubercle bacillus Mycobacterium Mycobacterium avium complex MAC bovis M avium complex infections caused by M avium complex M avium M intracellulare complex MAC 7 M kansasii 2 Hl MAC
397. QuantiFERON TB QFT BCG BCG QuantiFERON TB 2G Cellests BCG TB 2G X 10 1 X
398. WHO COM CRIED 5 OA HE S F fistulography WALES SBA PALO K amp S AS SAS transudate Light 1 gt 0 5 2 LDH LDH gt 0 6 3 LDH gt LDH 2 3 OF b MER VCE BLO
399. 27 40mm pneumothorax COPD
400. 53 11 7 COMPILES new quinolone compoumds new macrolide YY
401. CH oT BMH J juvenile tuberculosis tuberculosis in the young adult shunt gt Fis pressure controlled ventilation gt ATIF Wy mediastinal lymph node 3 3a fii 3b 4 45 6 superinfection HIV HI
402. FY AD 1973 BCG 1968 b epidemiological model
403. PD 74 potency of tuberculin 82 pre allergic phase 12 predicted vital capacity pred VC 111 pressure controlled ventilation 61 prevalance of symptomatics 110 Post primary initial focus prevalence rate of the registered 84 prevalence of disease 110 prevalence of infection 31 75 prevention of infection 26 preventive chemotherapy 111 previously infected person 31 primary complex 65 primary drug resistance 64 primary focus 64 primary infection 64 primary infection tuberculosis 64 primary infection type atypical mycobacterio sis 14 primary inoculation 65 primary lesion 64 primary lymph node lesion WRAY 64 primary tuberculosis 14 primary tuberculosis 65 primary vaccination 65 private public mix PPM 9 productive reaction 73 prohibition of work 61 proliferative reaction 97 propor
404. cavity RFP correspondence to an attending physi cian ioniazia isonicotinic acid hydrazide INH 1912 1952 11 RFP
405. ig defaulting deformity of thorax Lane 33 degree of dyspnea 53 delayed type allergy 78 delayed type hypersensitivity DTH 78 delayed type reaction EEM DUS deletion from TB NR IER desensitization desensitization destroyed lung ezki detection by health examination 49 detection by medical institutions 14 diagnostic criteria of atypical myco baceriosis JERA TE JE aE BY DUR AJE DD WT ARE 98 diagnostic criteria of nontuberculous myco baceriosis JERGA PE GEER PUREED 98 diffuse disseminated shadow 101 digestion decontamination procedure D 106 dihydro streptomycin DHSM 60 direct drug resistance test 80 direct method surgery 80 direct smear examination 84 80 disease stage of tuberculous thoracic empye ma KERO 45 disease status unknown 101 disseminated focus 59 disseminated lesion 59 disseminated lesion 59 disseminated shadow 59 dissemination 48
406. ih HR OB 1950 L 3 600 CHO 200 DARDHE CLA ZO CUE OD HBAS HY 200 1 1 continued treatment 6 2 continued home visit
407. k UE RUE SLI ABUT A HDD A R LE A ALU 63 TASB DAL X HME LAY HIEL L TD 1 k hyalinization J VRE HAE childhood type tuberculosis gt URAL HE tuberculosis in children childhood tuberculosis
408. mF aR AGH E EB ethambutol DILY YT hw ELISA enzyme linked immunosorbent assay ELISA emviomycin Ly EFI YY epituberculosis areynav7u yvA ethionamide IFAT LE EVM enviomycin DL EFI YY F FDA EB FDA EB stain TO AEFEH EO DOME CHS Fluo rescein diacetate EDA HIER FDA ethidium bromide EB G Global DOTS Target 1994 WHO DOTS
409. thorax ONS I SO MERT thoracoscope 20 33 CT L
410. 00 300 1 tuberculoma 1 cm X X tuberculous pleurisy WY 3 0g d7 80
411. 7 7 99 99 95 95 95 99 0 OFLX ofloxacin Pp PaCO2 arterial carbon dioxide partial pressure PaO arterial oxygen partial pressure PAS para amino salicylic acid DNTP LIVI F VAR SA patient s delay DRIVI he FAVA PCR PCR method persister DN YAI PH hydrogen exponent mp LHe A aT Pirquet DEN y PPD purified protein derivative DRINI YY PPM private public mix PPP public private partner ship PPP
412. A dormant DOTS Directly Observed Treatment Short course DOTS WHO 5 OR DOTS Plus DOTS WHO Stop TB Partner ship Dubos medium
413. ANY AIDS acquired immunodeficiency syndrome mrt K air fluid level gt air plombage ery AM atypical mycobacteriosis DIEA E anergy gt 7 AVE ARDS acute respiratory distress syndrome Huh HE Oz PEEP Bacille de Calmette Guerin gt BCG BACTEC BACTEC method 3 BACTEC460 TB
414. C BRAC 1d DIED RAL IBMT 3 D huffing treatment with fresh air and bed rest 1800 FET LAS CURE FEAR CO RE BI pathogen of category 3 4 AANI BAEC MEO DNT
415. CH2 C NH CH H O NH2 NH2 ARERR Ze E D ET A X CAPER ISIE DPT HCE viomycin VM 1951 Streptomyces floridae Streptomyces puniceus 1957 4 EVM VM 1986 Ly EJI VY extrapulmonary tuberculosis 1996 O
416. D KARA EBURA Mm thrombocytopenia 10 50x104 HD 50 000 ul RFP nodular shadow TH 4cm spa Sy Sem MIREA CE MPSS axb cm blood concentration blood level
417. HA BLOAT HE BEDRI E gt 4 mass infection inspissated cavity M
418. IL OME C asymptomatic pathogen carrier Muchs granule LD TIWI ARL WE 1 BUD F A Go PERLD BLAS T amp BS R 5 muramyl dipeptide L D D77 ay
419. SHE BCG M fortuitumfE M fortuitum EE infections caused by M fortuitum GAIT 4 M fortuitum M chelonae SHB VNTR CDH SITS M fortuitum OFLX MM kansasii infections caused by M kansasii A Ksgs7 M avium complex
420. TV aNY h mH WIRA SKE Ih AAE _ tuberculosis emergency dec laration 1999 7 26 1997 38 7 HEAR 43 WHO 1993 chemical constituents of tuber cle bacilli GAY TA D EE Ze A Pa ik DNA amp RNA 43
421. V HIV JE HIV 61 prohibition of work 28 DAK O work prohibition 18 RIED MES MILT S ROWE
422. X 19 19 Ogawa s medium proportion method Ogawas medium 19 Oka Katakura s medium 18 Oka s classification 18 old tuberculin OT 33 one second forced expiratory Volume rate FEVi 1 14 onset of tuberculosis 46 onset of tuberculosis following primary infec tion 64 onset of tuberculosis from recent converters 111 onset of tuberculosis from remotely infected 35 open healing 19 open lung biopsy 19 open negative cavity 37 openly healed cavity 63 opportunistic infection 101 optic nerve disturbance 59 order of hospital treatment 87 54 osteoarticular tuberculosis 54 other cavitary type 99 otitis media tuberculosa 78 outbreak of tuberculosis 62 outpatient treatment 19 oxygen concentrator 59 59 osteitis oxygen uptake VO P P nitro o acetylamino B hydroxypropiophe none NAP 8
423. aceum a M parmense i M saskatchewanense M shinshuense M avium subsp M branderi M avium subsp silvaticum avium M celatum M avium subsp hominissuis M intracellulare M genavense M gastri M malmoense M haemophilum M lepraemurium M ulcerans M nonchromogenicum M montefiorense M shimoidei M shottsii M shinshuense M triviale 4 M M terrae M triplex M avium subsp paratuberculosis M conspicuum M heidelbergense M lacus M sherrisii M abscessus M fortuitum subsp M agri M moriokaense M chelonae acetamidolyticum M aichiense M murale M fortuitum M goodii M album M obuense a M mageritense M alvei M parafortuitum M thermoresistibile M aurum M phlei M boenickei M austroafricanum M poriferae M brisbanense M brumae M pulveris M canariasense M chitae M rhodesiae M elephantis M chlorophenolicum M sphagni M houstonense M confluentis M tokaiense WV M immunogenum M chubuense M vaccae M manitobense M diernhoferi M vanbaalenii n M massiliense M duvalii M mucogenicum M fallax M neoaurum M flavescens M neworleansense M frederiksbergense M novocastrense M gadium M parmense M gilvum M peregrinum M hckensachense M porcinum M hassiacum M senegalense M hodleri M septicum M holsaticum M smegmatis M komossense M wolinskyi M madagascariense
424. al infection EL Ole CHIHI L CREST SB OR Mycobacterium avium BOT target point 1953 X 1 multi drug resistant tuberculosis MDRTB INH RFP REP 10 1 INH SM 10 1 76
425. ar sieve oxygen concentrator 32 Monaldi s drainage 38 monoclonal antibody 77 monotherapy 77 motivation for regular treatment 62 motivation for taking treatment 63 Ay 7I 109 multi drug resistance MDR 6 Much s granule multi drug resistant tuberculosis MDRTB 76 multi locular cavity 76 multinucleate d giant cell 76 multiple puncture method by a tube with 25 muramyl dipeptide 109 muscle flap plombage 37 mycobacteriophage 4A 7 7 Y 44 Mycobacterium avium M avium T Mycobacterium avium b Y RAK VA 85 Mycobacterium bovis 16 Mycobacterium growth indicator tube MGIT wG Mycobacterium tuberculosis multi needles MAH 42 Mycobacterium tuberculosis typus humanus e PARA 100 Mycobacterium 106 Mycobacterium 108 mycolicacid 108 N National Hospital Organization 54 natural resistance 60 natural resistance 72 negative conversion 15
426. ax MEMO Y 7 bOAMILEO F SUE tension cavity 0 DD X eee tt tension empyema pyothorax BAED mL PATE es chronic expanding ite BEFITS EM Cm ARTIR musce flap plombage REO p re
427. berculosis D D KRAAIE DATO FEI adult respiratory distress syndrome gt ARDS psychoneural disturbance CS ESI Wi TH SAR purified protein derivative PPD ALT HEM D gt D AP ERT S NY NV 6 8 OR Seibert WHO PPD S
428. em pleuropulmonary resection Ih LSE
429. facility designated for treating tuber culosis 60 medical facility mandated for diagnosis and treatment of tuberculosis 14 membrane type oxygen concentrator Kihia 107 mesenteric lymph node tuberculosis 79 metabolic acidosis 75 metabolic alkalosis 75 method of BCG vaccination BCG 9 microtiter method 106 middle lobe and lingula 79 middle lobe syndrome 79 middle lung field 79 Middlebrook media 3 FUT Wy 7 Heth 108 Middlebrook Dubos hemoagglutination test 108 miliary shadow WBE 74 miliary tuberculosis 74 miliary tuberculosis of early generalization type 73 miliary tuberculosis of late generalization type Wilt A WEISER 97 minimal inhibitory concentration MIC ix 57 mirror camera 108 mixed ventilatory impairment 55 moderately positive 79 molecular epidemiology 104 mediastinal lymph node molecul
430. gai 28C 37 CHE CL EPERE CH th amp NT AE Runyon LA CIPFA atypical nontu berculous mycobacteria 100 JE BOSS TA M tuberculosis 7 X HY W M bovis M africanum M microti Wi W M leprae M lepraemurium M paratubercu losis C amp 4 Runyon 4 PRAJE SARK atypical mycobacteriosis AM nontuberculous mycobacterio sis NTM JER TAPED UR A IC k RYE NTM AM 1956 JEE
431. gment length polymorphism 104 IS6110 RELP VNTR isolation culture FAROE CHAE DURA O BEAN Ze NACL NaOH dysequilibrium American Lung Association ALA
432. h thoracic empyema without bronchial fistula FSH WE A gt EF SCIE D A HIS K o THREE High amp EMEPENS I e cabna BV SRS SHE Z Ped Ze Va HB EE mandatory hospitalization m btn sterilizing action 109 RFP immune reconstitution syn drome IRS HIV HIV
433. horax a sputum pl ta 76 sputum cytology 21 sputum examination EYEE RO 20 stable non cavitary type 13 standard of tuberculosis medicine 42 standard therapy eee 101 statistics of tuberculosis 46 sterilizing action WEE 109 Stop TB Partnership Japan 68 streptomycin sulfate 113 streptomycin SM 68 strongly positive D 36 subculture 40 superinfection 61 surgical treatment 41 surgical treatment of thoracic empyema Sig 89 surveillance of BCG vaccination BCG 2 surveillance 58 survey on tuberculosis registry 46 susceptibility test 25 symptomatic visit to doctors 110 T Tcell 11 Tlymphocyte 11 Takahashi s kaolim agglutination test 76 target point I 76 110 technical assessment of BCG vaccination BCG
434. ittee for Chemotherapy of Tuber culosis GAKKEN classification 6 B C D E E 7 Ka Kb Kc Kd Kx Ky Kz school health examination X Lot p 1 2 10 20 active tuberculosis X
435. ke ZEEL MHE LE egg medium coagulated egg medium 1902 Dorset WHO MGIT h 772 physical therapy PT
436. l effect 58 bacteriological relapse FHER 58 bacteriological relapse rate 58 bacteriostatic action 68 bimodal distribution 87 blood concentration 49 blood gas analysis BGA 41 blood level 49 bone and joint tuberculosis 54 54 bone marrow puncture 54 booster phenomenon 103 A bone marrow biopsy bovine tubercle bacillus 16 145 Boyden s hemoagglutination test 447 105 breathing exercise BE 53 breathlessness 13 bronchial arteriography BAG 30 bronchial artery embolizaion BAE 30 bronchial biopsy 30 bronchial brushing 29 bronchial fistula 30 bronchial perforation 30 bronchial stenosis SEF 3Z4K 72 29 bronchial washing 30 28 bronchiectasis bronchiectasis 29 bronchiectasis 29 bronchoalveolar lavage BAL eee 30 bronchofiberscopy 30 bronchogenic ca
437. ld 22 lower lung field tuberculosis 22 lung abscess _ 91 lung cancer 91 lung field 95 lung infiltration Mii 92 lung physical therapy LPT 96 lung resection 93 lymph node perforation Y YX 114 lymphatic spread 113 113 83 L wenstein Jensen s medium L Jm 114 M macrophage 107 magnetic resonance imaging MRI 59 major drugs 14 management of regular drug taking BE 103 management standard 60 109 107 mass health examination 424 62 mass health examination 62 mass health examination for general inhabi tants 62 mass health examination for general inhabi tants 62 long term follow up results lympho hemic lyophilized vaccine mandatory hospitalization Mantoux s test mass infection 89 mass miniature radiophotography MMR 62 mass miniature radiophotography MMR 62 mechanical ventilation 66 752 WEN 7B 61 medical
438. lular growth 58 acinar shadow 1 0mm acinonodularlesion occupational therapy OT DPR SE F yay occupational therapist OT case index card
439. oculation BCG PD 1 uneven distribution of patients 105 unstable non cavitary type 102 upper lung field 63 urinary tract tuberculosis KIRRI 88 V vaccination 111 venous admixture 55 105 ventilator 66 ventilatory failure 23 ventilatory failure 53 Venturi s mask 105 vesicle 67 vestibular disturbance 71 video assisted thoracoscopic surgery VATS 12 viomycin VM 90 virulence WJ 38 virulence 84 ventilator visiting medical institutions visual disturbance 65 vital capacity VC 91 X volume controlled ventilation X ray classification of pulmonary tuberculo 62 sis 101 von PirquetC 102 Z W Ziehl Gabbets staining work prohibition 61 80 World AIDS Day 69 Ziehl Neelsen s staining World Health Organization WHO gt ZN 80 69 World TB Day 69 160 BAR Fort thse
440. oscopic empye ma cavity curettage O ER REET FH thoracoscopic lung biopsy thoracentesis pleural puncture 1000m tube drainage ONES AH
441. ous spread 113 hematothorax 48 hemic spread 48 hemoptysis Wifi 21 hemothorax 48 high dose therapy 76 high prevalence area 52 high risk group 96 high voltage radiography 49 highly virulent bacilli 35 hilar glandular tuberculosis 95 hilar lymph node 95 hilar shadow 95 home oxygen therapy HOT 5 home oxygen therapy HOT oe 57 home oxygen therapy HOT 106 home visit 22 hospitalDOTS 15 hospital treatment 87 household contacts examination 21 Hugh Jones degree of dyspnea 101 human immunodeficiency virus infection HIV 5 human tubercle bacillus 100 humoral immunity 17 hyalinization 63 hydrogen exponent pH 9 hypercapnemia 51 hypoxemia 82 Cin a 150 l iatrogenic 13 identification of atypical 99 identification test 83 idiopathic pleurisy
442. para amino salicylic acid PAS 97 partial resection 94 PAS 96 passive case finding 63 pathogen of category 3 74 patient s card indicating method of approved 154 treatment 25 patients delay 105 vital capacity VC 96 percutaneous inoculation 41 Pericostal tuberculosis 115 perifocal inflammation 61 periodic treatment progress report 82 peripheral nerve disorder 107 periproctal abscess _ 52 persister 60 persister 96 persisting bacilli 60 persisting bacteria 60 persisting cavity 13 photochromogen mycobacteria 98 photochromogenic mycobacteria 98 physical therapist PT 112 physical therapy PT 112 plain chest radiography 35 pleura 35 pleural adhesion and thickening 36 pleural adhesion MEIA 36 pleural biopsy 35 pleural calcification 35 pleural callosi
443. rcinoma 91 bronchography BG 30 broncholith 29 bronchoplasty 29 bronchoscopic examination 29 bronchoscopy 29 bronchus pl chi 28 C calcification 70 calcium deposit 70 canalicular dissemination 27 canalicular spread 27 cancellation from registry 84 capreomycin CPM 23 carbon dioxide narcosis 77 caries 23 case finding 25 case index card 58 24 case notification 24 case notification 97 case registration card 99 case registration card 24 caseation 27 caseoinfiltrative type lesion ie 66 caseous bronchitis 27 caseous degeneration 27 caseous lesion ZIK 27 case management caseous lymphangitis 27 caseous mass 27 caseous necrosis 27 caseous pneumonia 27 caseous pneumonia type lesion 27
444. tion 52 response rate to health examination lt 63 resting bacilli 32 resting bacteria 32 restriction fragment length polymorphism RFLP 10 restrictive ventilatory impairment 51 retained cavity 13 retreatment 57 revaccination 57 reversion 15 rifampicin RFP 112 right ventricular failure 16 right sided heart failure RHF 16 risk of infection 26 RobertKoch 54 rod form 23 routine health examination 82 S sagittal tomography 74 sanatorium 113 Sauton s medium 74 scar formation 97 school health examination 21 Schwartzman reaction oe 63 scotochromogen mycobacteria 13 scotochromogenic mycobacteria 13 scrofula scrofulosis 114 DALE 86 86 86 secondary infection type atypical mycobacte riosis see 86 secondary pneumothorax p E segmental resection segmental shadow
445. tion thin portion thin por tion 0 6um II pumorrhaphy alveoler pattern X pulmonary hilum
446. tion method 102 protein of tubercle bacilli PD 44 prothionamide 104 provision of treatment and education for tuberculosis children 113 provision of treatment for the handicapped children 13 psychoneural disturbance 68 public health center 106 public health nurse 106 public subsidy for medical treatment 15 pulmonary angiography PAG 93 pulmonary arterial pressure 93 pulmonary aspergillosis 90 pulmonary encephalopathy 92 93 pulmonary fistula 96 pulmonary function test _ 91 pulmonary hilum 94 pulmonary hypertension 92 pulmonary fibrosis pulmonary markings 95 pulmonary mycosis 92 pulmonary nocardiosis Ji 7 4 V X 7 JE 94 pulmonary physical therapy PPT 96 pulmonary sarcoidosis 92 pulmonary segmental resection 91 pulmonary suppuration Jil CIEE 91 pulmonary tuberculosis 91 pulmorrhaphy 94 purified protein derivative PPD 68 pyothorax JR
447. tion rate ESR chemokine 4 CXC CC CX3C C 4 D 7 G keloid BCG LS CP PIRES PED 1 2 SARRAIE DDD
448. ty 36 pleural callus WDEK 36 pleural effusion 34 pleural fluid examination 34 pleural puncture Meg WEER 34 pleurisy associated with secondary pul monary tuberculosis 67 pleurisy 35 Pleuropulmonaryresection 36 plombage of omental flap 75 pneumoconio tuberculosis 67 pneumoconiosis 67 pneumonectomy 93 pneumonectomy 93 pneumonectomy Wia 93 pneumothorax 31 pneumothorax therapy 32 polyclonal infection 76 polysaccharide of tubercle bacilli KAWZAS 44 portable oxygen 40 positive end expiratory pressure ventilation PEEP 52 positive tuberculin conversion after BCG vac cination BCG 2 positive tuberuculin conversion by tuberculo sis infection 60 86 post vaccination health monitoring 111 posteroanterior view radiography P A 94 postresection thoracoplasty 70 postural drainage 74 postural drainage
449. uble redness two step tuberculin skin test 1 3 2 2 BCG 1 2 WR BAN 1 2 8 10mm 6 8 7 niveau air fluid level X
450. ublic mix public private partnership pulmonary physical therapy physical therapy physical thera pist pyrazinamide QuantiFERON TB restriction fragment length poly morphism 143 RFP RHF RP RR SaO gt SCC SM Tbi TBGL TBLB Tc TH Th VATS VC VM VOs WHO XDR rifampicin right sided heart failure radiophotography relative risk arterial oxygen saturation short course chemotherapy streptomycin thioacetazone Tuberculous Glycolipids transbronchial lung biopsy cytotoxic T cells ethionamide helper T cells video assisted thoracoscopic sur gery vital capacity viomycin oxygen uptake World Health Organization extensively drug resistant A abscond from treatment accelerated reaction 73 accessory reaction of tuberculin test 103 accompanying pleurisy 67 acid fast bacilli sal ai i acid fastness acinar shadow 58 acinonodular lesion sat 58 acoustic 79 acquired drug resistance 32 acquired immunity 21 acquired immunodeficiency syndrome AIDS 51 acquired immunodeficiency syndrome AIDS 16 acquisition of drug resistance 75 active Protein antigen of tuberculin
451. xygen concentrator disseminated shadow disseminated lesion disseminated lesion focus NEAR Cdk EID D eR IE 59 ranking of causes of death 1950 1 1976 10 1999 21 1 2 E 3 1985 magnetic resonance imaging MRI
452. ydrazide 151 100 isonicotinic acid hydrazide INH 14 J Japan Anti Tuberculosis Association JATA 47 Japan International Cooperation Agency JICA 53 juvenile tuberculosis 61 K kanamycin KM 22 kaolin agglutination test 7 4 90 keloid 49 Kirchner s medium 37 Koch s bacillus 100 Koch s phenomenon 54 L Langhans giant cell 112 laryngeal tuberculosis 51 late generalization 97 latent tuberculosis infection PD 71 lateral tomography 74 lateral view radiography 73 lavage 30 light work required 111 lipid of tubercle bacilli 43 17 liquid medium 17 liquid vaccine 17 lobar shadow 96 lobectomy 96 lobular shadow 63 local reaction BCG 37 long term chemotherapy 79 liquefied oxygen 18 low virulent bacilli 61 lower lung fie

Download Pdf Manuals

Related Search

Related Contents

  Kensington BlackBelt 1st Degree Rugged Case for iPad® Air - Plum  Did you know? - Fresh Water Systems  théâtre paul scarron  Casio 3356 Watch User Manual    PDS-375 TR User`s Manual  

Copyright © All rights reserved. Failed to retrieve file